

Preterm birth: Risk factors, interventions for risk reduction, and maternal prognosis

Authors: [Julian N Robinson, MD](#), [Errol R Norwitz, MD, PhD, MBA](#)

Section Editor: [Charles J Lockwood, MD, MHCM](#)

Deputy Editor: [Vanessa A Barss, MD, FACOG](#)

All topics are updated as new evidence becomes available and our [peer review process](#) is complete.

Literature review current through: Oct 2018. | **This topic last updated:** Nov 06, 2018.

INTRODUCTION — Preterm birth refers to a delivery that occurs before 37 weeks of gestation. It may or may not be preceded by preterm labor. Seventy to eighty percent of preterm births (PTBs) ([table 1](#)) are spontaneous: due to preterm labor (40 to 50 percent) or preterm premature rupture of membranes (20 to 30 percent); rarely cervical insufficiency results in spontaneous preterm birth. The remaining 20 to 30 percent of PTBS are iatrogenic: due to maternal or fetal issues that jeopardize the health of the mother or fetus (eg, preeclampsia, placenta previa, abruptio placenta, fetal growth restriction, multiple gestation). Complications of pregnancy can lead to both spontaneous and provider-initiated preterm births.

Preterm birth is relatively common, occurring in 5 to 18 percent of births worldwide. (See ["Incidence and mortality of the preterm infant", section on 'Incidence'](#).) There are many risk factors for PTB ([table 2](#)) and many pathways from these risk factors to the terminal cascade of events resulting in labor. Preterm labor likely occurs when local uterine factors prematurely stimulate this cascade or suppressive factors that inhibit the cascade and maintain uterine quiescence are withdrawn prematurely. The four major factors leading to preterm labor are intrauterine infection, decidual hemorrhage, excessive uterine stretch, and maternal or fetal stress. Uteroplacental vascular insufficiency, exaggerated inflammatory response, hormonal factors, cervical insufficiency, and genetic predisposition also play a role. (See ["Pathogenesis of spontaneous preterm birth"](#).)

Ideally, identification of modifiable and nonmodifiable risk factors for PTB before conception or early in pregnancy will lead to interventions that help prevent this complication. However, few interventions have been proven to prolong pregnancy in women at risk. This goal has been elusive for several reasons: two-thirds of PTBs occur among women with no risk factors, causality has been difficult to prove (eg, a cofactor may be required thus complicating the chain of causality), and no adequate animal model exists for study of spontaneous PTB (sPTB).

Risk factors for PTB and potential interventions to mitigate risk, when possible, will be reviewed here. Pathogenesis of PTB and diagnosis and treatment of preterm labor are discussed separately:

- (See ["Pathogenesis of spontaneous preterm birth"](#).)

- (See ["Inhibition of acute preterm labor"](#).)
- (See ["Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment"](#).)

REPRODUCTIVE HISTORY

History of spontaneous preterm birth — A history of sPTB is the major risk factor for recurrence, and recurrences often occur at the same gestational age [1-3]. Women at highest risk are those with:

- No term pregnancy between the previous sPTB and the current pregnancy
- A history of multiple sPTBs

In large series, the frequency of recurrent sPTB was 15 to 30 percent after one sPTB and increased after two sPTBs [4-8]. The odds of recurrent sPTB in three high income countries (New Zealand, Sweden, Slovenia) ranged from 4.5 to 7.1, in one study [9]. Term births decrease the risk of sPTB in subsequent pregnancies (table 3 and table 4).

The risk of recurrent early sPTB is of particular concern given its high morbidity and mortality. In a large prospective series, approximately 5 percent of women who had an early sPTB at 23 to 27 weeks in their prior pregnancy delivered at <28 weeks in their subsequent pregnancy [4]. By comparison, if there was no previous history of sPTB, then the risk of sPTB <28 weeks was only 0.2 percent.

Other characteristics of the prior sPTB may also predict recurrence risk. In a small retrospective cohort study, women who presented with painless advanced cervical dilation were significantly more likely to have recurrent sPTB than women with a history of PPROM or PTL (55 versus 27 versus 32 percent, respectively) [10]. The increased risk remained after adjustment for gestational age of the last PTB.

Women who were born preterm are at modestly increased risk of having a sPTB compared with women who were born at term. (See ["Genetic factors"](#) below.)

A prior sPTB of twins, especially if before 34 weeks, is associated with an increased risk of sPTB in a subsequent singleton pregnancy [11,12]. The overall risk of sPTB in twin pregnancy is significantly higher in multiparous women whose previous singleton pregnancy was a sPTB: 67.3 percent versus 20.9 percent if the previous singleton delivery was at term (odds ratio 7.8, 95% CI 5.5-11.2) [13].

Intervention — Progesterone supplementation reduces the risk of PTB by approximately 30 percent in women with a singleton pregnancy and a history of spontaneous PTB. A review of evidence and treatment approaches is available separately. (See ["Progesterone supplementation to reduce the risk of spontaneous preterm birth"](#), section on ["Spontaneous singleton preterm birth in prior pregnancy"](#) and ["Progesterone supplementation to reduce the risk of spontaneous preterm birth"](#), section on ["Progesterone preparations and doses"](#).)

Sonographic measurement of cervical length in women with a history of PTB can identify those with a short cervix who may benefit from placement of a cerclage. Women with multiple second-trimester pregnancy losses/preterm births associated with painless cervical dilation may benefit from early placement of a cerclage based on this history alone (table 5). A review of screening and treatment approaches and supporting evidence is available separately.

- (See ["Second-trimester evaluation of cervical length for prediction of spontaneous preterm birth", section on 'Singleton pregnancy, prior spontaneous preterm singleton birth'.](#))
- (See ["Cervical insufficiency".](#))

A short interpregnancy interval has been associated with an increased risk of PTB. The March of Dimes encourages women to space pregnancies at least 18 months apart. (See ['Short interpregnancy interval'](#) below.)

Although an increase in uterine activity is a prerequisite for labor, randomized trials and a meta-analysis have shown that self-measurement of the frequency of uterine contractions by self-palpation/detection of signs of labor or through use of a home uterine activity monitor does not lead to a reduction in the rate of PTB [14,15]. Moreover, such an approach increases the frequency of unscheduled antenatal visits. The American College of Obstetricians and Gynecologists recommends not using home uterine activity monitoring as a screening strategy for prediction or prevention of PTB [16].

Prophylactic tocolytic therapy for prevention of PTB in high-risk asymptomatic women is not effective, although few randomized trials have been conducted [17,18]. (See ["Management of pregnant women after resolution of an episode of acute preterm labor".](#))

History of indicated preterm birth — A large retrospective cohort study assessed the risk of recurrent PTB by the type of PTB in the previous pregnancy [7]. The rate of recurrent PTB was 23 percent for women with a prior indicated PTB and 31.6 percent for women with a prior sPTB. Women with a prior indicated PTB were at particularly high risk for recurrent indicated PTB (relative risk [RR] 9.10, 95% CI 4.68-17.71) but also at increased risk of sPTB (RR 2.70, 95% CI 2.00-3.65). Women with a prior sPTB were at five- to sixfold increased risk for recurrent sPTB, but also appeared to be at slightly increased risk for indicated PTB (RR 1.61, 95% CI 0.98-2.67).

Intervention — Interventions to reduce the risk for recurrent indicated PTB depend on the indication for PTB. For example, administration of low-dose [aspirin](#) to women with a history of early delivery because of preeclampsia with severe features can reduce their risk for recurrent preeclampsia and PTB. (See ["Preeclampsia: Prevention", section on 'Low-dose aspirin'.](#))

History of abortion — In a 2015 systematic review of pregnancy outcome after uterine evacuation including over one million women (31 studies involving termination of pregnancy, five studies involving spontaneous abortion), women with a history of surgical uterine evacuation had a small but statistically significant increase in risk for PTB in a subsequent pregnancy compared with controls [19]. Women who underwent medical termination of pregnancy had a similar future risk of PTB as women with no history of pregnancy termination. Although surgical uterine evacuation appeared to be a risk factor for subsequent PTB, observational studies are flawed because they are subject to recall bias and inadequate adjustment of many of the other risk factors for adverse pregnancy outcome. (See ["Overview of pregnancy termination", section on 'Future pregnancies'](#) and ["Spontaneous abortion: Management", section on 'Future reproductive outcomes'.](#))

GENETIC FACTORS — Genetic polymorphisms appear to contribute to length of gestation and a woman's likelihood of sPTB. In a genomewide association study of a large cohort of women of European ancestry, maternal variants at the *EBF1*, *EEFSEC*, *AGTR2*, *WNT4*, *ADCY5*, and *RAP2C* loci were associated with gestational duration and maternal variants at the *EBF1*, *EEFSEC*, and *AGTR2* loci were associated with preterm birth; however, birth outcomes were self-

reported [20]. Although PTB susceptibility genes have been identified, epigenetic and gene-environmental factors probably play a more important role in PTB than the maternal genotype.

PTBs are more prevalent in some family pedigrees and racial groups, in women who were born preterm themselves, and in women with a first-degree female relative who had a PTB [21]. In addition, concordance for timing of parturition is higher in women who are monozygotic twins than in those who are dizygotic twins [3,22-32].

The paternal genotype does not have a significant effect on PTB. (See '[Paternal risk factors](#)' below.)

NON-HISPANIC BLACK RACE — In the United States, non-Hispanic blacks consistently have a higher rate of PTB than non-Hispanic whites [33]. In a systematic review and meta-analysis of eight English language studies including over 26 million singleton births, the odds of PTB were lowest in couples in which both parents were white and progressively increased with black parentage: white mother/white father (odds ratio [OR] 1.0), white mother/black father (OR 1.17), black mother/white father (OR 1.37), black mother/black father (OR 1.78) [34]. This may be related to both genetic and environmental factors (eg, social, educational, occupational, economic).

A discrepancy between black and white populations in the risk of recurrent PTB has also been observed. In black and white women whose first delivery was at 20 to 31 weeks of gestation, the frequency of a second delivery at the same gestational age range was 13.4 and 8.2 percent, respectively, in one study [4,35]. For the gestational age range 32 to 36 weeks, the frequency of a second delivery at the same gestational age was 3.8 and 1.9 percent, respectively.

Differences in epidemiologic and environmental risk factors account for some of the increased risk in PTB, but polymorphisms in genes for regulation of innate immunity also appear to play a role [36-39]. A woman's race/ethnicity seems to influence her microbiome and the impact of vaginal bacteria on PTB [40-43]. One mechanism may involve an enhanced proinflammatory response to normal or altered vaginal microflora, leading to preterm labor or preterm premature rupture of membranes (PPROM) [44]. Alternatively, immune hyporesponsiveness may create a permissive environment for ascending infection and its sequelae (preterm labor, PPRM) [45,46]. (See "[An overview of the innate immune system](#)".)

AGE — The rate of PTB is higher at the extremes of maternal age [47-49]. Physiologic immaturity and socioeconomic factors may increase risk for adolescent mothers; a higher prevalence of preexisting chronic disease and obesity may increase risk for older mothers. Both groups have high rates of unintended pregnancy; prevention of these pregnancies may reduce PTB [50].

CERVICAL SURGERY — Cold knife conization and loop electrosurgical excision procedures for treatment of cervical intraepithelial neoplasia have been associated with increased risks for late miscarriage and PTB. Possible mechanisms include loss of tensile strength from loss of cervical stroma, increased susceptibility for infection from loss of cervical glands, and loss of cervical plasticity from cervical scarring. (See "[Cervical intraepithelial neoplasia: Reproductive effects of treatment](#)".)

Intervention — Women undergoing treatment of cervical intraepithelial neoplasia should have the procedure that best diagnoses or prevents cervical cancer and also incurs the lowest risk of reproductive effects.

Although women who have undergone cervical surgery may develop cervical insufficiency, the pregnancy course and outcome need to be evaluated before making this diagnosis. We perform a

single transvaginal ultrasound measurement of cervical length measurement at 18 to 24 weeks in all women and treat those with a short cervix (≤ 25 mm) and no prior PTB with vaginal progesterone supplementation. (See ["Cervical insufficiency", section on 'Women with no prior second-trimester pregnancy loss/extremely preterm birth, but risk factors for cervical insufficiency'.](#))

UTERINE MALFORMATIONS

Congenital — In women with congenital uterine malformations, the magnitude of risk for PTB depends upon the specific abnormality [51-53].

Intervention — Surgical correction of the abnormality may reduce the risk for PTB. (See ["Congenital uterine anomalies: Surgical repair"](#).)

Acquired — Women with fibroids may be at slightly increased risk for pregnancy loss and PTB. A large fibroid (ie, ≥ 5 to 6 cm) or multiple fibroids appear to be the most important risk factors for PTB; a submucosal location is the most important risk factor for pregnancy loss. (See ["Pregnancy in women with uterine leiomyomas \(fibroids\)", section on 'Preterm labor and birth'.](#))

Intervention — Myomectomy before pregnancy may be indicated in women with pregnancy loss or early PTB (see ["Reproductive issues in women with uterine leiomyomas \(fibroids\)"](#)). Every effort should be made to avoid surgical removal of fibroids during pregnancy because of the risk for significant morbidity (hemorrhage). (See ["Pregnancy in women with uterine leiomyomas \(fibroids\)"](#).)

CHRONIC MEDICAL DISORDERS — Chronic maternal medical disorders can be associated with maternal or fetal complications necessitating medically indicated PTB as well as an increased risk for sPTB. Examples include women with hypertension, renal insufficiency, type 1 diabetes mellitus, some autoimmune diseases, and nonphysiologic anemia.

Both depression and exposure to selective serotonin reuptake inhibitors have been associated with an increased risk of PTB. (See ["Antenatal depression: Pregnancy and neonatal outcomes", section on 'Preterm birth'](#) and ["Antenatal use of antidepressants and risk of teratogenicity and adverse pregnancy outcomes: Selective serotonin reuptake inhibitors \(SSRIs\)", section on 'Preterm birth'.](#))

Intervention — Preconception identification and optimization of chronic medical diseases, such as diabetes and hypertension, can improve maternal health and pregnancy outcome. (See ["The preconception office visit"](#).)

Optimization of depression symptoms is also desirable. (See ["Unipolar major depression in pregnant women: General principles of treatment"](#).)

PREVIOUS INFANT WITH SUDDEN INFANT DEATH SYNDROME — A history of delivery of an infant who subsequently died from sudden infant death syndrome appears to be a risk factor for PTB in the following pregnancy [54]. (See ["Sudden infant death syndrome: Risk factors and risk reduction strategies"](#).)

ASSISTED REPRODUCTION — Pregnancies conceived by assisted reproduction are at higher risk for sPTB, even in the absence of multifetal gestation. The increased risk may be related to baseline maternal factors related to subfertility and/or factors related to assisted reproduction

procedures. (See ["Pregnancy outcome after assisted reproductive technology", section on 'Preterm birth, LBW, and SGA'.](#))

MULTIFETAL GESTATION — Multifetal gestation accounts for only 2 to 3 percent of all births but 17 percent of births before 37 weeks of gestation and 23 percent of births before 32 weeks. The widespread availability of assisted reproductive technology has resulted in a large increase in the incidence of multiple gestation; this increase, in turn, has led to an increase in spontaneous and indicated PTB [55].

The mechanism for sPTB in multifetal gestations, and particularly higher-order multifetal gestations, may be related to sequelae of increased uterine distension (see ["Pathogenesis of spontaneous preterm birth", section on 'Pathologic uterine distention'](#)). The endocrine environment produced by superovulation or the multiple pregnancy may also play a role. As an example, multifetal gestations produce increased amounts of estrogen, progesterone, and sex steroids compared with singleton pregnancies [56,57]. Increased steroid production may be a factor in initiation of labor (see ["Physiology of parturition"](#)). Higher circulating levels of relaxin associated with super-ovulation may cause cervical insufficiency with subsequent sPTB [58].

Intervention — Prevention and reduction of multifetal gestations, particularly high-order multifetal gestations, appear to improve neonatal outcome. (See ["Strategies to control the rate of high order multiple gestation"](#) and ["Multifetal pregnancy reduction and selective termination"](#).)

In unselected twin pregnancies, progesterone supplementation, use of a pessary, cerclage, and bed rest/reduction of physical activity do not prolong gestation. In women with a twin pregnancy and a prior singleton sPTB or a short cervix, the use of supplemental progesterone or a pessary is controversial and reviewed separately. (See ["Progesterone supplementation to reduce the risk of spontaneous preterm birth", section on 'Multiple gestation'](#) and ["Twin pregnancy: Prenatal issues", section on 'Preterm labor and delivery'](#).)

VAGINAL BLEEDING IN EARLY PREGNANCY — Early pregnancy bleeding is often due to decidual hemorrhage and associated with an increased risk for both subsequent spontaneous and indicated PTB. In a large study based on registry data, pregnancies with first-trimester bleeding were at increased risk for preterm premature rupture of membranes (PPROM) (odds ratio [OR] 1.18, 95% CI 1.01-1.37), placental abruption (OR 1.48, 95% CI 1.30-1.68), and severe preeclampsia (OR 1.25, 95% CI 1.09-1.43) [59]. In this and other studies, the association was stronger for PTB before 34 weeks than late PTB [59,60]. Women with persistent vaginal bleeding and bleeding in the second trimester are at higher risk of these complications than those with an isolated first-trimester event. (See ["Spontaneous abortion: Risk factors, etiology, clinical manifestations, and diagnostic evaluation", section on 'Threatened abortion'](#).)

Decidual hemorrhage results in release of tissue factor, which can trigger local thrombin formation. Decidual thrombin production has been associated with increased expression of soluble fms-like tyrosine kinase-1 (sFlt-1) and monocyte-recruiting chemokines, factors also associated with subsequent indicated PTB due to preeclampsia, abruption, or fetal growth restriction as well as subsequent sPTB [61]. Later in pregnancy, decidual cell-derived thrombin can inhibit decidual cell progesterone receptor expression, possibly resulting in PTB related to abruption or PPRM [62-64]. (See ["Pathogenesis of spontaneous preterm birth", section on 'Decidual hemorrhage'](#).)

Intervention — Women with a history of PTB may be treated with progesterone to prevent recurrence in a subsequent pregnancy. Those who have vaginal bleeding/abruption in the

subsequent pregnancy still appear to respond to [hydroxyprogesterone caproate](#) prophylaxis in that pregnancy [65].

SHORT CERVIX — There is an inverse relationship between cervical length measured by transvaginal ultrasound at 16 to 28 weeks of gestation and gestational age at delivery (table 6). A high Bishop or cervical score on digital examination is also associated with increased odds of PTB [66]. (See "[Second-trimester evaluation of cervical length for prediction of spontaneous preterm birth](#)".)

Intervention — For women with singleton pregnancies and no history of prior PTB, we suggest screening for a short cervix (≤ 25 mm) with a single examination at 18 to 24 weeks, which can be done in conjunction with the fetal anatomic survey ultrasound examination. Progesterone supplementation in this population reduces the risk for PTB. A review of evidence and treatment approaches are discussed in detail separately. (See "[Progesterone supplementation to reduce the risk of spontaneous preterm birth](#)", section on 'Short cervix in current pregnancy' and "[Progesterone supplementation to reduce the risk of spontaneous preterm birth](#)", section on 'Progesterone preparations and doses'.)

For women with singleton pregnancies and a history of prior PTB, we suggest serial measurements of cervical length, in agreement with most guidelines [67]. Cerclage may be indicated for those who develop a short cervix despite progesterone supplementation. We do not prescribe pessaries for women with a short cervix as the body of evidence does not support using a pessary to prolong gestation or improve neonatal outcome. (See "[Cervical insufficiency](#)", section on 'Ultrasound-based cervical insufficiency' and "[Cervical insufficiency](#)", section on 'Pessary'.)

Bedrest is not helpful — Bed rest is often recommended for women at increased risk for PTB [68]. While bed rest improves uteroplacental blood flow and can lead to a slight increase in birth weight, there is **no** evidence that it decreases the incidence of PTB [69-71], even in women with a short cervix [72,73]. Although underpowered, the only randomized trial attempting to determine whether hospitalization of women with arrested preterm labor improved outcome found hospitalized women had similar outcomes to those discharged home [74]. An observational study reported preterm birth was increased in women with a short cervix placed on activity restriction [72]. In addition, a pilot study in which women with a short cervix (≤ 20 mm) wore an activity tracker found that those who delivered preterm had fewer median number of steps/day than those who delivered at term (3576 versus 4554) [75].

Furthermore, bedrest has potential harms: it appears to increase the risk of thromboembolic events, has clear negative psychosocial effects, and leads to deconditioning [76-79].

DILATED CERVIX — Cervical dilation ≥ 1 cm before 24 weeks of gestation is associated with an increased risk of preterm birth and increasing cervical dilation is associated with increasing risk of preterm birth.

Intervention — In women with cervical insufficiency based on physical examination, emergency cerclage placement has been associated with a significant increase in prolongation of pregnancy and neonatal survival compared with expectant management. (See "[Cervical insufficiency](#)", section on 'Physical examination-based cervical insufficiency'.)

INFECTION — Multiple unrelated studies from varied disciplines (epidemiology, histopathology, microbiology, biochemistry, and maternal-fetal medicine) have reported an association between infection/inflammation and PTB, likely mediated by prostaglandins. The most consistent of these

observations come from placental pathologists who have described histological evidence of chorioamnionitis in the placentas of 20 to 75 percent of PTBs and positive membrane cultures in 30 to 60 percent of such patients [80-83]. In the Collaborative Perinatal Project, chorioamnionitis was detected in 6 percent of 43,940 deliveries evaluated [84]. The rate increased with decreasing gestational age: 15 percent at 28 to 32 weeks, 8 percent at 33 to 36 weeks, and 5 percent after 36 weeks of gestation. (See "[Pathogenesis of spontaneous preterm birth](#)", section on 'Bacteria'.)

Asymptomatic bacteriuria — It is unclear whether asymptomatic bacteriuria is an independent risk factor for PTB [85]. In one of the largest studies, the Cardiff Birth Survey, which prospectively studied over 25,000 births between 1970 and 1979, asymptomatic bacteriuria was not associated with a significant increase in the overall rate of PTB (odds ratio [OR] 1.21, 95% CI 0.96-1.53) [86], or sPTB (OR 1.07, 95% CI 0.78-1.46) [87] when the data were adjusted for demographic and social factors.

Intervention — A first-trimester urine culture should be performed on all pregnant women [88,89], and regular antenatal screening is recommended for women at high risk for asymptomatic bacteriuria (eg, women with sickle cell trait, recurrent urinary tract infections, diabetes mellitus, underlying renal disease). Reliance on symptoms to prompt screening is inadequate because symptoms such as frequency and nocturia are often attributed to the state of pregnancy. Pregnant women with asymptomatic bacteriuria should be treated with antibiotics to reduce their risk of developing pyelonephritis, and possibly to reduce the risk of PTB. (See "[Urinary tract infections and asymptomatic bacteriuria in pregnancy](#)", section on 'Asymptomatic bacteriuria'.)

In a systematic review and meta-analysis (14 randomized trials, overall poor quality), treatment of asymptomatic bacteriuria clearly and substantially decreased the incidence of asymptomatic bacteriuria (relative risk [RR] 0.25, 95% CI 0.14-0.48), pyelonephritis (relative risk [RR] 0.23, 95% CI 0.13-0.41) [90], and low birth weight (RR 0.66, 95% CI 0.49-0.89), but a difference in PTB was not established.

Periodontal disease — Periodontal disease is common in adults. Two systematic reviews have reported an association between periodontal disease and adverse pregnancy outcome, such as sPTB, but did not provide conclusive evidence that pregnancy complications, including sPTB, result from periodontal disease [91,92]. The included studies had different designs and used different criteria to diagnose periodontal disease and to define adverse outcome. Moreover, they generally did not adequately adjust for confounders or have adequate sample size to detect significant differences in pregnancy outcome. Oral bacteria that have been associated with both periodontal disease and PTB include *Tannerella forsythia*, *Porphyromonas gingivalis*, *Actinobacillus actinomycetemcomitans*, *Treponema denticola*, and *Fusobacterium nucleatum* [93-95].

Several hypotheses have been proposed to explain the association between periodontal disease and sPTB [96-99]. Periodontal flora may seed the fetoplacental unit and cause local inflammation, or inflammatory mediators of periodontal origin may cause systemic inflammation. An alternative, but equally reasonable, explanation is that periodontal disease is a marker of individuals who have a genetic predisposition towards an exaggerated local or systemic inflammatory response to a given stimulus (eg, bacteria), which leads to two separate adverse clinical events: periodontal disease and sPTB. Such individuals may also hyper-respond to vaginal bacteria with enhanced production of cytokines that lead to preterm labor or rupture of membranes. Thus, periodontal disease and preterm labor can be epidemiologically linked but not causally related.

Intervention — There is no strong evidence that treatment of periodontal disease improves pregnancy outcome. A joint consensus report of the European Federation of Periodontology and the American Academy of Periodontology in 2013 concluded that, although periodontal therapy is safe and leads to improved periodontal health in pregnant women, periodontal therapy does not reduce overall rates of PTB and low birth weight [100]. This conclusion was based on meta-analyses limited to higher-quality randomized trials that demonstrated no significant effect of nonsurgical periodontal treatment on rates of PTB or low birth weight [101-104]. Subsequent meta-analyses have reported similar findings [105].

Several hypotheses have been proposed in an attempt to explain why periodontal treatment has not been shown to reduce risk for adverse pregnancy outcomes. Possibilities include [106]:

- Lack of causality. Periodontitis may not be a direct or indirect cause of PTB or low birth weight.
- Shared risk factors may mitigate the effect of treatment. Some risk factors for both periodontitis and poor pregnancy outcome (eg, smoking) are not affected by periodontal treatment. Furthermore, PTB is likely the end result of a variety of environmental, behavioral, social, biological, and possibly genetic factors so periodontal treatment alone is unlikely to have a major impact on reducing risk.
- Underpowered trials. Very large trials would be required to detect significant reductions in very or extreme PTB rates since these are much less common than late PTBs.
- Lack of a consistent definition of periodontal disease. This has led to inclusion of women with mild disease whose pregnancies may not benefit from treatment.
- Treatment of periodontal disease in the trials was inadequate to affect pregnancy outcome. To demonstrate a beneficial effect, treatment may have to start before pregnancy or very early in pregnancy, continue longer, or be more intense. If PTB is related to changes in the genital tract microbiome induced by changes in the oral microbiome, local treatment of oral inflammation may not reverse genital tract changes.

Genital tract infection — Multiple studies have reported an association between preterm labor/delivery and various genital tract infections (table 7), including group B streptococci (GBS) [107], *Chlamydia trachomatis* [108-111], bacterial vaginosis [112-114], *Neisseria gonorrhoea* [115], syphilis [116], *Trichomonas vaginalis* [117], *Ureaplasma* species [118], and unencapsulated *Haemophilus influenzae* [119]. A positive culture correlates with the presence of histologic chorioamnionitis; however, causal relationships for most of these infections and PTB have not been proven and are controversial [107,120,121].

Intervention

- **Role of routine screening** – Some treatment trials have reported a reduction in PTB with routine screening and treatment for infection in the early second trimester, while others have reported no benefit. Discordant findings may be due to confounding by recolonization or reinfection after therapy, intercurrent use of nonprotocol antibiotics, and failure to culture fastidious bacteria (eg, *Mycoplasma hominis*, *Ureaplasma urealyticum*) leading to misclassifications of women as noninfected.
- **Role of empiric antibiotic therapy** – Empiric antibiotic therapy does not reduce PTB. A 2007 meta-analysis of 17 randomized trials evaluated use of prophylactic antibiotics for prevention

of PTB based on abnormal vaginal flora (12 trials), a previous PTB (three trials), and a positive fetal fibronectin test result (two trials) [122]. There was no significant association between antibiotic treatment and reduction in PTB regardless of the criteria used to assess risk, the antimicrobial drug administered, or gestational age at time of treatment (overall combined random effect for delivery at less than 37 weeks RR 1.03, 95% CI 0.86-1.24). A 2015 systematic review of randomized trials also concluded that antibiotic prophylaxis in the second or third trimester did not reduce the risk of preterm prelabor rupture of membranes (RR 0.31, 95% CI 0.06-1.49, one trial 229 women) or PTB (RR 0.85, 95% CI 0.64-1.14, five trials, 1480 women); however, the included studies were of low methodological quality [123]. Subsequent trials have also not shown a benefit [124].

- **Chlamydia, gonorrhea, syphilis** – There is no evidence that treatment of chlamydia, gonorrhea, or syphilis prolongs gestation. The only controlled trial that evaluated the effect of treatment of chlamydia on gestational duration did not show a reduction in PTB [125]. However, screening for and treatment of these infections is recommended to prevent other maternal and neonatal sequelae. (See "[Clinical manifestations and diagnosis of *Neisseria gonorrhoeae* infection in adults and adolescents](#)" and "[Treatment of uncomplicated *Neisseria gonorrhoeae* infections](#)" and "[Syphilis in pregnancy](#)" and "[Treatment of *Chlamydia trachomatis* infection](#)".)
- **Bacterial vaginosis, *Ureaplasma*, GBS** – Prospective controlled studies and meta-analyses have reported either a modest or no effect of antibiotic treatment on prolonging gestation in asymptomatic women who screened positive for bacterial vaginosis [126-130], *Ureaplasma urealyticum* [131,132], or GBS [133], although these studies are undoubtedly confounded by recolonization or reinfection after therapy and intercurrent use of nonprotocol antibiotics. GBS screening in late pregnancy and chemoprophylaxis for prevention of early-onset neonatal GBS infection is recommended. (See "[Neonatal group B streptococcal disease: Prevention](#)".)

Women with bacterial vaginosis and a previous PTB may benefit from bacterial vaginosis screening and treatment, but there are insufficient data to recommend this as a routine practice. This subject is discussed in detail separately. (See "[Bacterial vaginosis: Treatment](#)", [section on 'Pregnant women'](#).)
- ***Trichomonas*** – Screening and treatment of asymptomatic *Trichomonas* infection in HIV-negative women is not recommended during pregnancy because there is no convincing evidence that it reduces the risk for PTB [134-139]. In contrast, screening and treatment are recommended for HIV-positive women to reduce the risks for pelvic inflammatory disease and vertical transmission of HIV [140]. (See "[Trichomoniasis](#)", [section on 'Pregnant women'](#).)

Malaria — Malaria is associated with PTB, low birth weight, and other maternal and neonatal morbidities [141]. (See "[Malaria in pregnancy: Epidemiology, clinical manifestations, diagnosis, and outcome](#)".)

Intervention — Prevention of malaria infection and treatment of established malaria infection can reduce the risk for PTB [142-144]. (See "[Malaria in pregnancy: Prevention and treatment](#)".)

BEHAVIOR

Short interpregnancy interval — A short interpregnancy interval has been associated with an increased risk for PTB, even if the previous delivery was at term [145]. The risk is highest in women with a previous PTB. In a study of 263 women with consecutive sPTBs and 299 women

with consecutive term births, an interpregnancy interval ≤ 6 months more than tripled the risk for sPTB less than 34 weeks in the second pregnancy after adjustment of confounders; the risk for late preterm birth was not affected [146]. (See "[Interpregnancy interval and obstetrical complications](#)", section on 'Preterm birth' and "[Interpregnancy interval and obstetrical complications](#)", section on 'Preterm prelabor rupture of membranes'.)

Intervention — Increasing the interval between pregnancies to at least 12 months may reduce a woman's risk for sPTB. In a large cohort study that examined the impact of postpartum contraceptive coverage and use within 18 months of birth in preventing PTB, postpartum contraceptive coverage was protective against PTB [147]. For every month of contraceptive coverage, odds of PTB <37 weeks decreased by 1.1 percent.

The March of Dimes encourages women to space pregnancies at least 18 months apart. However, the interval between pregnancies should not be excessive. A meta-analysis calculated that an interval ≥ 60 months also increased the risk for PTB (OR 1.20, 95% CI 1.17-1.24) [148].

Occupational physical activity — A relationship between maternal physical activity related to working during pregnancy and PTB has not been clearly established because available evidence is generally of low quality. A meta-analysis of 21 studies including a total of 146,457 women identified a high cumulative work fatigue score as the strongest work-related risk factor for PTB (odds ratio 1.63, 95% CI 1.33-1.98) [149]. The results of this analysis are summarized in the table (table 8). Another meta-analysis reported PTB was associated with standing and walking at work for more than 3 hours per day (OR 1.3, 95% CI 1.1-1.6), lifting and carrying >5 kg (OR 1.3, 95% CI 1.05-1.6), lifting and carrying in the third trimester (OR 1.3, 95% CI 1.01-1.8), and having a job that required physical effort or physical exertion (OR 1.4, 95% CI 1.19-1.66) [150]. A large European case-control study noted employed women were at higher risk of PTB if they worked longer than 42 hours/week, stood more than six hours/day, or had low job satisfaction [151].

It is probably important to quantitate all of the factors involved in work-related exertion, as well as the mother's ability to handle stress and fatigue, to gain insight into this controversy. In addition, a "healthy worker" effect is likely present in many studies whereby healthier workers are more likely to continue to work, work longer hours, and work in more demanding jobs, thus biasing outcomes. (See "[Working during pregnancy](#)", section on 'Work on pregnancy and child development'.)

Intervention — Women with uncomplicated pregnancies who are employed where there are no greater potential hazards than those encountered in routine daily life may continue to work without interruption until the onset of labor. Nevertheless, the physical demands of the woman's job should be considered, especially in women at high risk of PTB.

The effects of reducing occupational fatigue have not been evaluated in randomized trials. Maternity legislation in many European countries has regulated work schedules and working conditions for pregnant women; however, none of the European countries except France have experienced a reduction in PTB rates [152]. Nevertheless, paid maternity leave, guaranteed job protection, and regulation of hazardous working conditions remain desirable societal goals.

Bedrest is not helpful. (See "[Bedrest is not helpful](#)" above.)

Exercise — In randomized trials of women with uncomplicated pregnancies, exercise during pregnancy did not increase the risk for PTB [153]. A systematic review of prospective cohort, case-cohort, nested case-control or randomized study design found that exercise (leisure time physical activity) was not associated with an increased risk of PTB, and may decrease the risk by 10 to 14

percent compared with physical inactivity [154]. The optimum time appeared to be two to four hours of physical activity/week. As discussed above, a "healthy exerciser" effect likely exists whereby healthier women and those at low risk of PTB are more likely to continue to exercise during pregnancy. However, it has also been hypothesized that exercise may reduce the risk of PTB by reducing oxidative stress or increasing placental vascularization [155]. (See "[Exercise during pregnancy and the postpartum period](#)".)

Coitus — Sexual intercourse is not a risk factor for PTB; therefore, abstinence after pregnancy has been achieved has no role in strategies for prevention of PTB. [156-159].

Smoking — Cigarette smoking has a modest dose-dependent relationship with the risk for PTB [3,86,160-166]. This effect may be explained by increased rates of smoking-related complications of pregnancy, such as placental abruption, placenta previa, premature rupture of membranes, and intrauterine growth restriction. However, the association still exists when adjustment is made for these possible confounding factors, suggesting that there may be a direct effect of cigarette smoking on spontaneous preterm labor and delivery [166]. (See "[Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate](#)".)

Intervention — Smoking cessation should always be encouraged for its general health benefits. It is likely that smokers who decrease or stop cigarette smoking will reduce their risk for PTB, but this has not been proven. (See "[Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate](#)", section on 'Preterm birth' and "[Cigarette smoking in pregnancy: Cessation strategies and treatment options](#)".)

Since 2010, in the United States, Medicaid programs are required to cover tobacco-cessation counseling and drug therapy for pregnant women without cost sharing, which might increase utilization of these services [167].

Substance use — Maternal substance use increases the risk of PTB, but it is difficult to separate the risk attributable to the substance from other risk factors, which are common in these patients [86,163-166,168-172]. In one study, women with cocaine-positive urine samples were at fourfold increased risk of developing preterm labor [170]. Another series found positive urine toxicology in 24 of 141 (17 percent) of women with preterm labor compared with 3 of 108 (2.8 percent) controls with uncomplicated labor at term [169]. Cocaine was the most common substance identified and was detected in approximately 60 percent of women in preterm labor with positive toxicology tests. Alcohol [171] and toluene [172] are additional substances associated with an increased risk of preterm labor. In women who use multiple drugs, risk of PTB has been reported to range from 25 to 63 percent [173,174]. (See "[Substance use by pregnant women](#)" and "[Alcohol intake and pregnancy](#)".)

Intervention — Health care providers should attempt to identify maternal substance use, provide information on the maternal and fetal risks associated with this practice, and help patients to stop using these drugs. It is likely that this will reduce their risk for PTB, but this has not been proven. (See "[Substance use by pregnant women](#)" and "[Overview of management of opioid use disorder during pregnancy](#)" and "[Methadone and buprenorphine pharmacotherapy of opioid use disorder during pregnancy](#)".)

DIET — Women with adequate nutrition and a normal body mass index have better pregnancy outcomes than other women, which suggests that nutritional interventions may have a role in preventing PTB in selected populations.

There is some evidence supporting the hypothesis that maternal undernutrition in pregnancy results in PTB [175]. In sheep, moderate maternal undernutrition around the time of conception results in accelerated maturation of the fetal hypothalamic-pituitary-adrenal axis, a precocious fetal cortisol surge, and PTB [176,177]. In Gambian women, pregnancies conceived during the rainy season when food is scarce were significantly shorter than those conceived when food was more plentiful [178]. Observations of shorter gestational length with early pregnancy exposure to the Dutch famine also support this hypothesis [179]. Thus, focusing on dietary events around the time of conception may be important in prevention of some cases of PTB.

Intervention — In systematic reviews, isocaloric protein supplements [180], balanced protein/energy supplements [181], and high protein supplements [181] did not reduce the rate of PTB. Most studies show that vitamin supplements during pregnancy do not reduce the risk of PTB [182-188], although they have other benefits. There may be potential benefits of micronutrient supplementation in specific subpopulations of pregnant women, such as those who are undernourished or HIV-infected [189].

The effect of fish oil supplements on PTB has been studied in randomized trials and no benefit was found. The effect of fish consumption on length of gestation has only been evaluated in observational studies, which have reported discordant results. In these studies, the benefits of fish consumption may be confounded by socioeconomic level, avoidance of more harmful foods that fish replaces, beneficial effects of nutrients in fish other than n-3 long-chain polyunsaturated fatty acids, and/or other attributes that are discordant between fish consumers and non-consumers. If there is a true reduction, it is likely to be modest. These data are discussed separately. (See "[Fish consumption and docosahexaenoic acid \(DHA\) supplementation in pregnancy](#)".)

WEIGHT AND WEIGHT CHANGES — Extremes of prepregnancy weight and/or body mass index have been associated with increased rates of PTB [190-193]. The strength of this association is not well-defined because the effect is bimodal as opposed to linear and because of interdependent variables [194]. For example, low prepregnancy weight may be confounded by socioeconomic status, race/ethnicity, and even weight gain in pregnancy.

Obese gravida are at increased risk of iatrogenic PTB resulting from medical complications. Obesity also appears to increase the risk for preterm premature rupture of membranes (PPROM) and decrease the risk of sPTB without PPRM. (See "[Obesity in pregnancy: Complications and maternal management](#)", section on 'Indicated and spontaneous preterm birth'.)

Low and high weight gain during pregnancy have also been associated with PTB [195-197]. These issues are discussed in detail separately. (See "[Gestational weight gain](#)".)

Intervention — Although some evidence suggests that weight loss in obese women before pregnancy and appropriate weight gain in pregnancy can reduce the risk for PTB, the evidence is not definitive. In a systematic review of randomized trials of the effects of dietary and lifestyle interventions in pregnancy on maternal weight and obstetric outcomes, PTB was not statistically reduced (relative risk 0.78, 95% CI 0.60-1.02, 13 trials, 2652 women) [198]. However, these trials had significant heterogeneity and were of low quality. (See "[Obesity in pregnancy: Complications and maternal management](#)" and "[Gestational weight gain](#)".)

Regardless of its effect on pregnancy, weight loss before pregnancy should be recommended for obese women because of general health benefits. (See "[Overweight and obesity in adults: Health consequences](#)".)

Women with eating disorders can also benefit from intervention. (See "[Eating disorders in pregnancy](#)".)

HEIGHT — Women with shorter stature appear to be at increased risk for preterm birth and taller women appear to be decreased risk [[199-201](#)].

STRESS — Most women report experiencing at least one stressful life event in the year before giving birth [[202](#)]. An association between stress (including post-traumatic stress disorder) and PTB is biologically plausible. There is evidence that maternal and fetal stress activates cells in the placenta, decidua, and fetal membranes to produce corticotropin-releasing hormone (CRH) [[203](#)]. CRH can enhance local prostaglandin production, which initiates contractions. However, studies have not consistently demonstrated a relationship between maternal stress, CRH concentration, and PTB [[204-206](#)]. (See "[Pathogenesis of spontaneous preterm birth](#)", section on '[Activation of the HPA axis](#)'.)

When maternal psychosocial stress has been associated with an increased risk of PTB, the risk was modest: OR 1.42 (95% CI 1.05-1.91) in cohort studies [[207](#)]. Analysis of data is complicated by difficulty defining and measuring maternal stress, assessments at different times during pregnancy, variations in adjustment of confounders, lack of differentiation between acute and chronic stressors, and discordant baseline characteristics of the populations studied [[208](#)].

Intervention — Although social support during pregnancy has resulted in improvements in immediate psychosocial outcome, it has not been shown to significantly reduce the rate of PTB in stressed gravida. A 2003 systematic review concluded that social support was not sufficiently powerful to improve the obstetrical outcome of the pregnancy in which it was provided, possibly because of the immense social deprivation experienced by most of the women in the trials examined [[209](#)].

There are limited data on other interventions for reducing stress in pregnant women (eg, relaxation or mind-body therapies [eg, meditation, massage, yoga, breathing exercises, music therapy, aromatherapy]). Available trials are small and of poor quality; clear effects on birth outcome have not been proven [[210](#)].

ENVIRONMENT — Systematic reviews have reported an association between PTB and fine particulate matter in air [[211-213](#)]. Although the effect was small and limited by differences in study designs, particularly assessment of exposure, a causal effect is possible.

In a study that used birth records and US Energy Information Administration data to evaluate the relationship between the retirements of eight power plants and PTB in California, retirement of the power plants was associated with reductions in moderate and late PTBs for those living 0 to 5 km and 5 to 10 km away compared with controls living 10 to 20 km away [[214](#)]. The authors hypothesized that air pollution may increase the risk for PTB by activation of proinflammatory cytokines or by increasing the risks for preeclampsia, growth restriction, or maternal susceptibility to infection.

SUBOPTIMAL PRENATAL CARE — The absence of prenatal care has been consistently identified as a risk factor for preterm labor and delivery, but it is less clear whether this association is causal or a marker for other factors that contribute to PTB. (See "[Prenatal care: Initial assessment](#)" and "[Prenatal care: Second and third trimesters](#)".)

Intervention — Retrospective studies cannot be adequately controlled to adjust for confounding factors, while randomized trials (no prenatal care versus standard care) would be unethical.

Therefore, the only well-designed studies on the effect of prenatal care on PTB compare standard with enhanced care (ie, some combination of patient education, case management, home visits, nutrition counseling, and extra prenatal visits and cervical examinations).

Regular prenatal care should be encouraged and improves perinatal outcome in women with underlying medical disorders (eg, diabetes, chronic hypertension, thyroid disease) or pregnancy-related conditions (eg, preeclampsia); however, the March of Dimes trial discussed below suggests enhanced care is unlikely to decrease the incidence of PTB.

The March of Dimes Multicenter Prematurity Prevention Trial assigned 2395 women with singleton or multiple gestations at high risk for PTB to either standard of care or an enhanced care intervention (more frequent prenatal visits, improved patient education regarding symptoms and signs of preterm labor, and weekly pelvic examinations after 20 to 24 weeks of gestation) [14]. There was no significant difference between the two groups in sPTB rates. A meta-analysis that included three trials of women with singleton pregnancies also found no clear evidence that specialized antenatal clinics reduced PTB [215].

PRETERM LABOR — Uterine contractions are an essential component of labor, but mild irregular contractions are a normal finding at all stages of pregnancy, thereby adding to the challenge of distinguishing true labor (contractions that result in cervical change) from false labor (contractions that do not result in cervical change, ie, Braxton-Hicks contractions). Only 13 percent of women presenting at <34 weeks of gestation and meeting explicit contraction criteria for preterm labor deliver within one week. (See "[Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment](#)".)

Intervention — Tocolytic therapy of an acute episode of idiopathic preterm labor often abolishes contractions temporarily but does not remove the underlying stimulus that initiated the process of parturition or reverse parturitional changes in the uterus. The net effect is that tocolytics are unlikely to prolong pregnancy by weeks or months. However, short-term tocolysis is endorsed by most guidelines since delivery can often be delayed for at least 48 hours enabling glucocorticoids given to the mother to achieve their maximum fetal effect [67]. (See "[Inhibition of acute preterm labor](#)".)

FETAL FACTORS — Male sex is a risk factor for sPTB [216-219]. Certain congenital anomalies [220,221] and growth restriction [222-227] are risk factors for spontaneous and indicated PTB. For example, congenital anomalies may lead to polyhydramnios, which increases the risk for preterm labor and PPRM.

PATERNAL RISK FACTORS — No paternal risk factors for development of PTB in their partners have been identified [228]. PTB risk does **not** appear to be affected by the father's history of preterm children with other women or PTBs to members of the father's family [229].

PREDICTING RISK FOR PRETERM BIRTH

Risk scoring systems — Risk scoring is a quantitative method used to identify women at increased risk for PTB. Proposed systems typically calculate an additive score based on points assigned to arbitrarily selected or weighted epidemiological, historical, and clinical risk factors [86,165,166,168].

Systematic reviews have concluded that there is no effective risk scoring system for prediction of PTB [230,231]. This is due to our lack of knowledge regarding the cause(s) of PTB in most women and because the most powerful risk factor is previous PTB, which is not applicable to nulliparous

women. The positive predictive value (the percent of women defined as high risk that actually go on to have a PTB) of most risk scoring systems is low, 20 to 30 percent, and varies according to the population studied [169].

Biomarkers — Cervicovaginal fetal fibronectin (fFN) can be a useful biomarker for predicting PTB within 7 to 14 days in women with contractions and mild cervical dilation and effacement, particularly when combined with ultrasound assessment of cervical length and when a quantitative measurement is available. The predictive value of fFN for PTB more than 14 days after testing is poor. (See "[Preterm labor: Clinical findings, diagnostic evaluation, and initial treatment](#)", section on '[<34 weeks of gestation](#)'.)

Fetal fibronectin may be useful for predicting risk of PTB in asymptomatic high-risk women (eg, previous preterm birth). A fFN ≥ 50 ng/mL at 22 to 27^{6/7}ths weeks of gestation had sensitivity 55 percent and positive predictive value 27 percent for prediction of PTB <34 weeks in one study [232]. An algorithm combining quantitative fFN (not available in the United States) and cervical length, demographic information, and obstetric history (whether previous spontaneous preterm birth/preterm premature rupture of membranes or current suspected preterm labor) has been incorporated into an App (QUIPP) for prediction of spontaneous PTB in Europe [233,234].

In contrast, fFN is not useful as a screening test for predicting risk of PTB in asymptomatic nulliparous women. In the largest prospective cohort study of use of fFN in asymptomatic low-risk nulliparous women with singleton pregnancies and cervical length >15 mm (n = 9410), the sensitivity and positive predictive value of fFN ≥ 50 ng/mL at 22 to 30 weeks of gestation for preterm birth <32 weeks was 32.1 and 3.1 percent, respectively [235]. Using a lower or higher threshold did not significantly improve overall test performance.

A test (PreTRM Test) for two serum proteins, insulin-like growth factor-binding protein 4 (IBP4) and sex hormone-binding globulin (SHBG), became available for clinical use to predict preterm birth in 2017. In a study to develop and validate a mass spectrometry-based serum test to predict spontaneous preterm delivery in asymptomatic pregnant women, the test had sensitivity and specificity of 0.75 and 0.74, respectively, for predicting preterm birth <37 weeks [236]. We do not recommend moving forward with serum screening for preterm birth until such screening has been adequately tested and validated.

Over 30 other biomarkers have been studied for identification of asymptomatic women at high risk of PTB. A 2011 systematic review of these biomarkers included 72 observational studies involving almost 90,000 women and concluded that **none** of these other biomarkers (alone or in combination) was clinically useful for predicting sPTB in asymptomatic women [237]. The markers included inflammation-related biomarkers, placental protein/hormone-related biomarkers, angiogenesis-related biomarkers, coagulation-related biomarkers, genetic-biomarkers, and proteomic-related biomarkers.

PROMISING INTERVENTIONS UNDER INVESTIGATION

Low-dose aspirin — It has been hypothesized that low-dose [aspirin](#) may reduce the risk of spontaneous PTB (sPTB) by inhibition of the inflammatory and uteroplacental ischemia pathways leading to this outcome ([algorithm 1](#)) (see "[Pathogenesis of spontaneous preterm birth](#)"). The following lines of evidence support this hypothesis:

- In a meta-analysis of individual participant data from trials that evaluated use of antiplatelet agents in women at high risk for developing preeclampsia, antiplatelet agents reduced the risk

of sPTB <34 weeks of gestation in the high-risk population (RR 0.86, 95% CI 0.76-0.99) and also <37 weeks [238].

- In a secondary analysis of data from a randomized trial of use of low-dose [aspirin](#) in healthy nulliparous women at low risk for developing preeclampsia, low-dose aspirin reduced the rate of sPTB <34 weeks in the low-risk population as well (OR 0.46, 95% CI 0.23-0.89, after adjustment for variables such as body mass index, race, tobacco use, marital status, and education level) but not sPTB <37 weeks [239].

Although these findings are promising, large randomized trials need to be performed evaluating the use of low-dose [aspirin](#) for reduction of sPTB as a primary outcome in women at high and low risk of sPTB. Until such data are available, we agree with American College of Obstetricians and Gynecologists guidelines that low-dose aspirin should not be used in an attempt to prevent sPTB [240].

LONG-TERM MATERNAL CONSEQUENCES OF PRETERM BIRTH — Women who deliver preterm are at increased risk for cardiovascular morbidity and mortality years after the delivery. In a 2015 systematic review and meta-analysis of 10 cohort studies, women who had a spontaneous preterm delivery were at higher risk for the following cardiovascular events when compared with women who delivered at term and followed for 12 to 35 years postpartum [241]:

- Fatal and nonfatal ischemic heart disease (hazard ratio [HR] 1.38, 95% CI 1.22-1.57)
- Fatal and nonfatal stroke (HR 1.71, 95% CI 1.53-1.91)
- Fatal and nonfatal overall cardiovascular disease (HR 2.01, 95% CI: 1.52-2.65)

It is unclear why spontaneous preterm delivery appears to be a marker for later cardiovascular disease or whether women who delivered preterm should be identified by primary care providers and encouraged to optimize modifiable risk factors for cardiovascular disease more than women without this history. (See "[Overview of primary prevention of coronary heart disease and stroke](#)".)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "[Society guideline links: Preterm labor and birth](#)".)

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

- Basics topic (see "[Patient education: Preterm labor \(The Basics\)](#)")

- Beyond the Basics topics (see "[Patient education: Preterm labor \(Beyond the Basics\)](#)" and "[Patient education: Bacterial vaginosis \(Beyond the Basics\)](#)" and "[Patient education: Management of a cervical biopsy with precancerous cells \(Beyond the Basics\)](#)")

SUMMARY AND RECOMMENDATIONS

- There are many risk factors for preterm labor and delivery ([table 2](#)). Some are reversible, others are permanent. Identification of risk factors for spontaneous preterm birth (sPTB) before conception or early in pregnancy ideally would lead to interventions that could help prevent this complication.
- Prior PTB is the strongest risk factor for future PTB, and recurrences often occur at the same gestational age. The frequency of recurrent PTB is 15 to 30 percent after one PTB and up to 60 percent after two PTBs. Term births decrease the risk of PTB in subsequent pregnancies ([table 3](#) and [table 4](#)). (See "[History of spontaneous preterm birth](#)" above.)
- For women with a history of sPTB, progesterone supplementation reduces the risk of recurrent sPTB by approximately 30 percent. (See "[Progesterone supplementation to reduce the risk of spontaneous preterm birth](#)", section on '[Spontaneous singleton preterm birth in prior pregnancy](#)'.)
- Short cervical length on transvaginal ultrasound examination between 18 and 24 weeks of gestation in the current pregnancy is a risk factor for PTB and is the basis for screening for a short cervix in the midtrimester. (See "[Short cervix](#)" above.)
 - For women with no previous history of sPTB who develop a short cervix, progesterone supplementation may prolong gestation. (See "[Progesterone supplementation to reduce the risk of spontaneous preterm birth](#)", section on '[Short cervix in current pregnancy](#)'.)
 - For women with a history of sPTB who develop a short cervix despite progesterone supplementation, placement of a cerclage may prolong gestation. (See "[Cervical insufficiency](#)".)
- Interventions that have general health benefits and may reduce risk of PTB include smoking cessation, treatment of drug misuse, treatment of asymptomatic bacteriuria, and maintenance of a normal body mass index. (See "[Smoking](#)" above and "[Substance use](#)" above and "[Asymptomatic bacteriuria](#)" above and "[Weight and weight changes](#)" above.)
- Avoiding an interpregnancy interval of less than six months, and ideally less than 12 months, may reduce a woman's risk for sPTB. (See "[Short interpregnancy interval](#)" above.)
- Singleton gestations are less likely to deliver preterm than multiple gestations. Prevention and reduction of multifetal gestations, particularly high-order multifetal gestations, can reduce the risk of preterm birth. (See "[Multifetal gestation](#)" above.)
- No biomarker performs well as a screening test for predicting spontaneous preterm birth in asymptomatic low risk women. (See "[Biomarkers](#)" above.)

Use of UpToDate is subject to the [Subscription and License Agreement](#).

REFERENCES

1. Bloom SL, Yost NP, McIntire DD, Leveno KJ. Recurrence of preterm birth in singleton and twin pregnancies. *Obstet Gynecol* 2001; 98:379.
2. Esplin MS, O'Brien E, Fraser A, et al. Estimating recurrence of spontaneous preterm delivery. *Obstet Gynecol* 2008; 112:516.
3. Bhattacharya S, Raja EA, Mirazo ER, et al. Inherited predisposition to spontaneous preterm delivery. *Obstet Gynecol* 2010; 115:1125.
4. Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 1999; 181:1216.
5. Lykke JA, Paidas MJ, Langhoff-Roos J. Recurring complications in second pregnancy. *Obstet Gynecol* 2009; 113:1217.
6. Kristensen J, Langhoff-Roos J, Kristensen FB. Implications of idiopathic preterm delivery for previous and subsequent pregnancies. *Obstet Gynecol* 1995; 86:800.
7. Laughon SK, Albert PS, Leishear K, Mendola P. The NICHD Consecutive Pregnancies Study: recurrent preterm delivery by subtype. *Am J Obstet Gynecol* 2014; 210:131.e1.
8. Yamashita M, Hayashi S, Endo M, et al. Incidence and risk factors for recurrent spontaneous preterm birth: A retrospective cohort study in Japan. *J Obstet Gynaecol Res* 2015; 41:1708.
9. Ferrero DM, Larson J, Jacobsson B, et al. Cross-Country Individual Participant Analysis of 4.1 Million Singleton Births in 5 Countries with Very High Human Development Index Confirms Known Associations but Provides No Biologic Explanation for 2/3 of All Preterm Births. *PLoS One* 2016; 11:e0162506.
10. Drassinower D, Običan SG, Siddiq Z, et al. Does the clinical presentation of a prior preterm birth predict risk in a subsequent pregnancy? *Am J Obstet Gynecol* 2015; 213:686.e1.
11. Rafael TJ, Hoffman MK, Leiby BE, Berghella V. Gestational age of previous twin preterm birth as a predictor for subsequent singleton preterm birth. *Am J Obstet Gynecol* 2012; 206:156.e1.
12. Schaaf JM, Hof MH, Mol BW, et al. Recurrence risk of preterm birth in subsequent singleton pregnancy after preterm twin delivery. *Am J Obstet Gynecol* 2012; 207:279.e1.
13. Schaaf JM, Hof MH, Mol BW, et al. Recurrence risk of preterm birth in subsequent twin pregnancy after preterm singleton delivery. *BJOG* 2012; 119:1624.
14. Multicenter randomized, controlled trial of a preterm birth prevention program. Collaborative Group on Preterm Birth Prevention. *Am J Obstet Gynecol* 1993; 169:352.
15. Urquhart C, Currell R, Harlow F, Callow L. Home uterine monitoring for detecting preterm labour. *Cochrane Database Syst Rev* 2017; 2:CD006172.
16. Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists. Practice bulletin no. 130: prediction and prevention of preterm birth. *Obstet Gynecol* 2012; 120:964. Reaffirmed 2018.
17. Whitworth M, Quenby S. Prophylactic oral betamimetics for preventing preterm labour in singleton pregnancies. *Cochrane Database Syst Rev* 2008; :CD006395.

18. Khanprakob T, Laopaiboon M, Lumbiganon P, Sangkomkarn US. Cyclo-oxygenase (COX) inhibitors for preventing preterm labour. *Cochrane Database Syst Rev* 2012; 10:CD007748.
19. Saccone G, Perriera L, Berghella V. Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis. *Am J Obstet Gynecol* 2016; 214:572.
20. Zhang G, Feenstra B, Bacelis J, et al. Genetic Associations with Gestational Duration and Spontaneous Preterm Birth. *N Engl J Med* 2017; 377:1156.
21. Boivin A, Luo ZC, Audibert F, et al. Risk for preterm and very preterm delivery in women who were born preterm. *Obstet Gynecol* 2015; 125:1177.
22. Ward K, Argyle V, Meade M, Nelson L. The heritability of preterm delivery. *Obstet Gynecol* 2005; 106:1235.
23. Clausson B, Lichtenstein P, Cnattingius S. Genetic influence on birthweight and gestational length determined by studies in offspring of twins. *BJOG* 2000; 107:375.
24. Hao K, Wang X, Niu T, et al. A candidate gene association study on preterm delivery: application of high-throughput genotyping technology and advanced statistical methods. *Hum Mol Genet* 2004; 13:683.
25. Treloar SA, Macones GA, Mitchell LE, Martin NG. Genetic influences on premature parturition in an Australian twin sample. *Twin Res* 2000; 3:80.
26. Annells MF, Hart PH, Mullighan CG, et al. Interleukins-1, -4, -6, -10, tumor necrosis factor, transforming growth factor-beta, FAS, and mannose-binding protein C gene polymorphisms in Australian women: Risk of preterm birth. *Am J Obstet Gynecol* 2004; 191:2056.
27. Winkvist A, Mogren I, Högberg U. Familial patterns in birth characteristics: impact on individual and population risks. *Int J Epidemiol* 1998; 27:248.
28. Macones GA, Parry S, Elkousy M, et al. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. *Am J Obstet Gynecol* 2004; 190:1504.
29. Kistka ZA, DeFranco EA, Ligthart L, et al. Heritability of parturition timing: an extended twin design analysis. *Am J Obstet Gynecol* 2008; 199:43.e1.
30. Velez DR, Fortunato S, Thorsen P, et al. Spontaneous preterm birth in African Americans is associated with infection and inflammatory response gene variants. *Am J Obstet Gynecol* 2009; 200:209.e1.
31. Svensson AC, Sandin S, Cnattingius S, et al. Maternal effects for preterm birth: a genetic epidemiologic study of 630,000 families. *Am J Epidemiol* 2009; 170:1365.
32. Wilcox AJ, Skjaerven R, Lie RT. Familial patterns of preterm delivery: maternal and fetal contributions. *Am J Epidemiol* 2008; 167:474.
33. Centers for Disease Control and Prevention. Preterm birth. <http://www.cdc.gov/reproductivehealth/maternalinfanthealth/pretermbirth.htm> (Accessed on April 14, 2016).
34. Srinivasjois RM, Shah S, Shah PS, Knowledge Synthesis Group on Determinants Of Preterm/LBW Births. Biracial couples and adverse birth outcomes: a systematic review and meta-analyses. *Acta Obstet Gynecol Scand* 2012; 91:1134.

35. Iams JD, Goldenberg RL, Mercer BM, et al. The Preterm Prediction Study: recurrence risk of spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 1998; 178:1035.
36. Manuck TA, Lai Y, Meis PJ, et al. Admixture mapping to identify spontaneous preterm birth susceptibility loci in African Americans. *Obstet Gynecol* 2011; 117:1078.
37. Genc MR, Onderdonk A. Endogenous bacterial flora in pregnant women and the influence of maternal genetic variation. *BJOG* 2011; 118:154.
38. Tsai HJ, Hong X, Chen J, et al. Role of African ancestry and gene-environment interactions in predicting preterm birth. *Obstet Gynecol* 2011; 118:1081.
39. Frey HA, Stout MJ, Pearson LN, et al. Genetic variation associated with preterm birth in African-American women. *Am J Obstet Gynecol* 2016; 215:235.e1.
40. Wen A, Srinivasan U, Goldberg D, et al. Selected vaginal bacteria and risk of preterm birth: an ecological perspective. *J Infect Dis* 2014; 209:1087.
41. Fettweis JM, Brooks JP, Serrano MG, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. *Microbiology* 2014; 160:2272.
42. Hyman RW, Fukushima M, Jiang H, et al. Diversity of the vaginal microbiome correlates with preterm birth. *Reprod Sci* 2014; 21:32.
43. Vinturache AE, Gyamfi-Bannerman C, Hwang J, et al. Maternal microbiome - A pathway to preterm birth. *Semin Fetal Neonatal Med* 2016; 21:94.
44. Genc MR, Witkin SS, Delaney ML, et al. A disproportionate increase in IL-1 β over IL-1 α in the cervicovaginal secretions of pregnant women with altered vaginal microflora correlates with preterm birth. *Am J Obstet Gynecol* 2004; 190:1191.
45. Simhan HN, Caritis SN, Krohn MA, et al. Decreased cervical proinflammatory cytokines permit subsequent upper genital tract infection during pregnancy. *Am J Obstet Gynecol* 2003; 189:560.
46. Simhan HN, Krohn MA. First-trimester cervical inflammatory milieu and subsequent early preterm birth. *Am J Obstet Gynecol* 2009; 200:377.e1.
47. Fuchs F, Monet B, Ducruet T, et al. Effect of maternal age on the risk of preterm birth: A large cohort study. *PLoS One* 2018; 13:e0191002.
48. Lawlor DA, Mortensen L, Andersen AM. Mechanisms underlying the associations of maternal age with adverse perinatal outcomes: a sibling study of 264 695 Danish women and their firstborn offspring. *Int J Epidemiol* 2011; 40:1205.
49. Fraser AM, Brockert JE, Ward RH. Association of young maternal age with adverse reproductive outcomes. *N Engl J Med* 1995; 332:1113.
50. Shapiro-Mendoza CK, Barfield WD, Henderson Z, et al. CDC Grand Rounds: Public Health Strategies to Prevent Preterm Birth. *MMWR Morb Mortal Wkly Rep* 2016; 65:826.
51. Koike T, Minakami H, Kosuge S, et al. Uterine leiomyoma in pregnancy: its influence on obstetric performance. *J Obstet Gynaecol Res* 1999; 25:309.
52. Davis JL, Ray-Mazumder S, Hobel CJ, et al. Uterine leiomyomas in pregnancy: a prospective study. *Obstet Gynecol* 1990; 75:41.
53. Rice JP, Kay HH, Mahony BS. The clinical significance of uterine leiomyomas in pregnancy. *Am J Obstet Gynecol* 1989; 160:1212.

54. Smith GC, Wood AM, Pell JP, Dobbie R. Sudden infant death syndrome and complications in other pregnancies. *Lancet* 2005; 366:2107.
55. Kiely JL. What is the population-based risk of preterm birth among twins and other multiples? *Clin Obstet Gynecol* 1998; 41:3.
56. TambyRaja RL, Ratnam SS. Plasma steroid changes in twin pregnancies. *Prog Clin Biol Res* 1981; 69A:189.
57. Muechler EK, Huang KE. Plasma estrogen and progesterone in quintuplet pregnancy induced with menotropins. *Am J Obstet Gynecol* 1983; 147:105.
58. Weiss G, Goldsmith LT, Sachdev R, et al. Elevated first-trimester serum relaxin concentrations in pregnant women following ovarian stimulation predict prematurity risk and preterm delivery. *Obstet Gynecol* 1993; 82:821.
59. Lykke JA, Dideriksen KL, Lidegaard O, Langhoff-Roos J. First-trimester vaginal bleeding and complications later in pregnancy. *Obstet Gynecol* 2010; 115:935.
60. Szymusik I, Bartnik P, Wypych K, et al. The association of first trimester bleeding with preterm delivery. *J Perinat Med* 2015; 43:525.
61. Lockwood CJ. Risk factors for preterm birth and new approaches to its early diagnosis. *J Perinat Med* 2015; 43:499.
62. Lockwood CJ, Kayisli UA, Stocco C, et al. Abruption-induced preterm delivery is associated with thrombin-mediated functional progesterone withdrawal in decidual cells. *Am J Pathol* 2012; 181:2138.
63. Mackenzie AP, Schatz F, Krikun G, et al. Mechanisms of abruption-induced premature rupture of the fetal membranes: Thrombin enhanced decidual matrix metalloproteinase-3 (stromelysin-1) expression. *Am J Obstet Gynecol* 2004; 191:1996.
64. Lockwood CJ, Toti P, Arcuri F, et al. Mechanisms of abruption-induced premature rupture of the fetal membranes: thrombin-enhanced interleukin-8 expression in term decidua. *Am J Pathol* 2005; 167:1443.
65. Manuck TA, Esplin MS, Biggio J, et al. Predictors of response to 17-alpha hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth. *Am J Obstet Gynecol* 2016; 214:376.e1.
66. Newman RB, Goldenberg RL, Iams JD, et al. Preterm prediction study: comparison of the cervical score and Bishop score for prediction of spontaneous preterm delivery. *Obstet Gynecol* 2008; 112:508.
67. Medley N, Poljak B, Mammarella S, Alfirevic Z. Clinical guidelines for prevention and management of preterm birth: a systematic review. *BJOG* 2018; 125:1361.
68. Fox NS, Gelber SE, Kalish RB, Chasen ST. The recommendation for bed rest in the setting of arrested preterm labor and premature rupture of membranes. *Am J Obstet Gynecol* 2009; 200:165.e1.
69. Goldenberg RL, Cliver SP, Bronstein J, et al. Bed rest in pregnancy. *Obstet Gynecol* 1994; 84:131.
70. Sciscione AC. Maternal activity restriction and the prevention of preterm birth. *Am J Obstet Gynecol* 2010; 202:232.e1.
71. Sosa CG, Althabe F, Belizán JM, Bergel E. Bed rest in singleton pregnancies for preventing preterm birth. *Cochrane Database Syst Rev* 2015; :CD003581.

72. Grobman WA, Gilbert SA, Iams JD, et al. Activity restriction among women with a short cervix. *Obstet Gynecol* 2013; 121:1181.
73. Fox NS, Jean-Pierre C, Predanic M, Chasen ST. Does hospitalization prevent preterm delivery in the patient with a short cervix? *Am J Perinatol* 2007; 24:49.
74. Yost NP, Bloom SL, McIntire DD, Leveno KJ. Hospitalization for women with arrested preterm labor: a randomized trial. *Obstet Gynecol* 2005; 106:14.
75. Zemet R, Schiff E, Manovitch Z, et al. Quantitative assessment of physical activity in pregnant women with sonographic short cervix and the risk for preterm delivery: A prospective pilot study. *PLoS One* 2018; 13:e0198949.
76. Kovacevich GJ, Gaich SA, Lavin JP, et al. The prevalence of thromboembolic events among women with extended bed rest prescribed as part of the treatment for premature labor or preterm premature rupture of membranes. *Am J Obstet Gynecol* 2000; 182:1089.
77. Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. *Cochrane Database Syst Rev* 2010; :CD000110.
78. Abdul Sultan A, West J, Tata LJ, et al. Risk of first venous thromboembolism in pregnant women in hospital: population based cohort study from England. *BMJ* 2013; 347:f6099.
79. Convertino VA, Bloomfield SA, Greenleaf JE. An overview of the issues: physiological effects of bed rest and restricted physical activity. *Med Sci Sports Exerc* 1997; 29:187.
80. Norwitz ER, Robinson JN, Challis JR. The control of labor. *N Engl J Med* 1999; 341:660.
81. Salafia CM, Vogel CA, Vintzileos AM, et al. Placental pathologic findings in preterm birth. *Am J Obstet Gynecol* 1991; 165:934.
82. Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth. *Am J Obstet Gynecol* 2004; 190:1493.
83. Goldenberg RL, Andrews WW, Hauth JC. Choriodecidual infection and preterm birth. *Nutr Rev* 2002; 60:S19.
84. Williams MC, O'Brien WF, Nelson RN, Spellacy WN. Histologic chorioamnionitis is associated with fetal growth restriction in term and preterm infants. *Am J Obstet Gynecol* 2000; 183:1094.
85. Schnarr J, Smaill F. Asymptomatic bacteriuria and symptomatic urinary tract infections in pregnancy. *Eur J Clin Invest* 2008; 38 Suppl 2:50.
86. Meis PJ, Michielutte R, Peters TJ, et al. Factors associated with preterm birth in Cardiff, Wales. I. Univariable and multivariable analysis. *Am J Obstet Gynecol* 1995; 173:590.
87. Meis PJ, Michielutte R, Peters TJ, et al. Factors associated with preterm birth in Cardiff, Wales. II. Indicated and spontaneous preterm birth. *Am J Obstet Gynecol* 1995; 173:597.
88. Connolly A, Thorp JM Jr. Urinary tract infections in pregnancy. *Urol Clin North Am* 1999; 26:779.
89. Uncu Y, Uncu G, Esmer A, Bilgel N. Should asymptomatic bacteriuria be screened in pregnancy? *Clin Exp Obstet Gynecol* 2002; 29:281.
90. Smaill F, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. *Cochrane Database Syst Rev* 2007; :CD000490.
91. Xiong X, Buekens P, Fraser WD, et al. Periodontal disease and adverse pregnancy outcomes: a systematic review. *BJOG* 2006; 113:135.

92. Vergnes JN, Sixou M. Preterm low birth weight and maternal periodontal status: a meta-analysis. *Am J Obstet Gynecol* 2007; 196:135.e1.
93. Offenbacher S, Jared HL, O'Reilly PG, et al. Potential pathogenic mechanisms of periodontitis associated pregnancy complications. *Ann Periodontol* 1998; 3:233.
94. Newnham JP, Shub A, Jobe AH, et al. The effects of intra-amniotic injection of periodontopathic lipopolysaccharides in sheep. *Am J Obstet Gynecol* 2005; 193:313.
95. Han YW, Redline RW, Li M, et al. *Fusobacterium nucleatum* induces premature and term stillbirths in pregnant mice: implication of oral bacteria in preterm birth. *Infect Immun* 2004; 72:2272.
96. Kornman KS, di Giovine FS. Genetic variations in cytokine expression: a risk factor for severity of adult periodontitis. *Ann Periodontol* 1998; 3:327.
97. Galbraith GM, Steed RB, Sanders JJ, Pandey JP. Tumor necrosis factor alpha production by oral leukocytes: influence of tumor necrosis factor genotype. *J Periodontol* 1998; 69:428.
98. Kornman KS, Crane A, Wang HY, et al. The interleukin-1 genotype as a severity factor in adult periodontal disease. *J Clin Periodontol* 1997; 24:72.
99. Boggess KA, Moss K, Madianos P, et al. Fetal immune response to oral pathogens and risk of preterm birth. *Am J Obstet Gynecol* 2005; 193:1121.
100. Sanz M, Kornman K, Working group 3 of joint EFP/AAP workshop. Periodontitis and adverse pregnancy outcomes: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. *J Clin Periodontol* 2013; 40 Suppl 14:S164.
101. Polyzos NP, Polyzos IP, Zavos A, et al. Obstetric outcomes after treatment of periodontal disease during pregnancy: systematic review and meta-analysis. *BMJ* 2010; 341:c7017.
102. Uppal A, Uppal S, Pinto A, et al. The effectiveness of periodontal disease treatment during pregnancy in reducing the risk of experiencing preterm birth and low birth weight: a meta-analysis. *J Am Dent Assoc* 2010; 141:1423.
103. Chambrone L, Pannuti CM, Guglielmetti MR, Chambrone LA. Evidence grade associating periodontitis with preterm birth and/or low birth weight: II: a systematic review of randomized trials evaluating the effects of periodontal treatment. *J Clin Periodontol* 2011; 38:902.
104. Kim AJ, Lo AJ, Pullin DA, et al. Scaling and root planing treatment for periodontitis to reduce preterm birth and low birth weight: a systematic review and meta-analysis of randomized controlled trials. *J Periodontol* 2012; 83:1508.
105. Schwendicke F, Karimbux N, Allareddy V, Gluud C. Periodontal treatment for preventing adverse pregnancy outcomes: a meta- and trial sequential analysis. *PLoS One* 2015; 10:e0129060.
106. Michalowicz BS, Gustafsson A, Thumbigere-Math V, Buhlin K. The effects of periodontal treatment on pregnancy outcomes. *J Clin Periodontol* 2013; 40 Suppl 14:S195.
107. Valkenburg-van den Berg AW, Sprij AJ, Dekker FW, et al. Association between colonization with Group B Streptococcus and preterm delivery: a systematic review. *Acta Obstet Gynecol Scand* 2009; 88:958.
108. Martin DH, Koutsky L, Eschenbach DA, et al. Prematurity and perinatal mortality in pregnancies complicated by maternal *Chlamydia trachomatis* infections. *JAMA* 1982; 247:1585.

109. Andrews WW, Goldenberg RL, Mercer B, et al. The Preterm Prediction Study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. *Am J Obstet Gynecol* 2000; 183:662.
110. Ryan GM Jr, Abdella TN, McNeeley SG, et al. Chlamydia trachomatis infection in pregnancy and effect of treatment on outcome. *Am J Obstet Gynecol* 1990; 162:34.
111. Cohen I, Veille JC, Calkins BM. Improved pregnancy outcome following successful treatment of chlamydial infection. *JAMA* 1990; 263:3160.
112. Hillier SL, Nugent RP, Eschenbach DA, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. *N Engl J Med* 1995; 333:1737.
113. Meis PJ, Goldenberg RL, Mercer B, et al. The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *Am J Obstet Gynecol* 1995; 173:1231.
114. Bretelle F, Rozenberg P, Pascal A, et al. High *Atopobium vaginae* and *Gardnerella vaginalis* vaginal loads are associated with preterm birth. *Clin Infect Dis* 2015; 60:860.
115. Edwards LE, Barrada MI, Hamann AA, Hakanson EY. Gonorrhea in pregnancy. *Am J Obstet Gynecol* 1978; 132:637.
116. Watson-Jones D, Chagalucha J, Gumodoka B, et al. Syphilis in pregnancy in Tanzania. I. Impact of maternal syphilis on outcome of pregnancy. *J Infect Dis* 2002; 186:940.
117. Silver BJ, Guy RJ, Kaldor JM, et al. *Trichomonas vaginalis* as a cause of perinatal morbidity: A systematic review and meta-analysis. *Sex Transm Dis* 2014; 41:369.
118. Sweeney EL, Kallapur SG, Gisslen T, et al. Placental Infection With *Ureaplasma* species Is Associated With Histologic Chorioamnionitis and Adverse Outcomes in Moderately Preterm and Late-Preterm Infants. *J Infect Dis* 2016; 213:1340.
119. Collins S, Ramsay M, Slack MP, et al. Risk of invasive *Haemophilus influenzae* infection during pregnancy and association with adverse fetal outcomes. *JAMA* 2014; 311:1125.
120. Andrews WW, Klebanoff MA, Thom EA, et al. Midpregnancy genitourinary tract infection with *Chlamydia trachomatis*: association with subsequent preterm delivery in women with bacterial vaginosis and *Trichomonas vaginalis*. *Am J Obstet Gynecol* 2006; 194:493.
121. Mancuso MS, Figueroa D, Szychowski JM, et al. Midtrimester bacterial vaginosis and cervical length in women at risk for preterm birth. *Am J Obstet Gynecol* 2011; 204:342.e1.
122. Simcox R, Sin WT, Seed PT, et al. Prophylactic antibiotics for the prevention of preterm birth in women at risk: a meta-analysis. *Aust N Z J Obstet Gynaecol* 2007; 47:368.
123. Thinkhamrop J, Hofmeyr GJ, Adetoro O, et al. Antibiotic prophylaxis during the second and third trimester to reduce adverse pregnancy outcomes and morbidity. *Cochrane Database Syst Rev* 2015; 1:CD002250.
124. Bellad MB, Hoffman MK, Mallapur AA, et al. Clindamycin to reduce preterm birth in a low resource setting: a randomised placebo-controlled clinical trial. *BJOG* 2018; 125:1601.
125. Martin DH, Eschenbach DA, Cotch MF, et al. Double-Blind Placebo-Controlled Treatment Trial of *Chlamydia trachomatis* Endocervical Infections in Pregnant Women. *Infect Dis Obstet Gynecol* 1997; 5:10.
126. Leitich H, Brunbauer M, Bodner-Adler B, et al. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis. *Am J Obstet Gynecol* 2003; 188:752.

127. Carey JC, Klebanoff MA, Hauth JC, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *N Engl J Med* 2000; 342:534.
128. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. *Cochrane Database Syst Rev* 2000; :CD000262.
129. Haahr T, Ersbøll AS, Karlsen MA, et al. Treatment of bacterial vaginosis in pregnancy in order to reduce the risk of spontaneous preterm delivery - a clinical recommendation. *Acta Obstet Gynecol Scand* 2016; 95:850.
130. Subtil D, Brabant G, Tilroy E, et al. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. *Lancet* 2018.
131. Eschenbach DA, Nugent RP, Rao AV, et al. A randomized placebo-controlled trial of erythromycin for the treatment of *Ureaplasma urealyticum* to prevent premature delivery. The Vaginal Infections and Prematurity Study Group. *Am J Obstet Gynecol* 1991; 164:734.
132. Raynes-Greenow CH, Roberts CL, Bell JC, et al. Antibiotics for ureaplasma in the vagina in pregnancy. *Cochrane Database Syst Rev* 2004; :CD003767.
133. Klebanoff MA, Regan JA, Rao AV, et al. Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci. *Am J Obstet Gynecol* 1995; 172:1540.
134. Klebanoff MA, Carey JC, Hauth JC, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. *N Engl J Med* 2001; 345:487.
135. Koss CA, Baras DC, Lane SD, et al. Investigation of metronidazole use during pregnancy and adverse birth outcomes. *Antimicrob Agents Chemother* 2012; 56:4800.
136. Kigozi GG, Brahmabhatt H, Wabwire-Mangen F, et al. Treatment of *Trichomonas* in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda. *Am J Obstet Gynecol* 2003; 189:1398.
137. Mann JR, McDermott S, Zhou L, et al. Treatment of trichomoniasis in pregnancy and preterm birth: An observational study. *J Womens Health (Larchmt)* 2009; 18:493.
138. Gülmezoglu AM, Azhar M. Interventions for trichomoniasis in pregnancy. *Cochrane Database Syst Rev* 2011; :CD000220.
139. Stringer E, Read JS, Hoffman I, et al. Treatment of trichomoniasis in pregnancy in sub-Saharan Africa does not appear to be associated with low birth weight or preterm birth. *S Afr Med J* 2010; 100:58.
140. Workowski KA, Bolan GA, Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. *MMWR Recomm Rep* 2015; 64:1.
141. Aidoo M, McElroy PD, Kolczak MS, et al. Tumor necrosis factor-alpha promoter variant 2 (TNF2) is associated with pre-term delivery, infant mortality, and malaria morbidity in western Kenya: Asembo Bay Cohort Project IX. *Genet Epidemiol* 2001; 21:201.
142. Luntamo M, Kulmala T, Mbewe B, et al. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. *Am J Trop Med Hyg* 2010; 83:1212.

143. Wolfe EB, Parise ME, Haddix AC, et al. Cost-effectiveness of sulfadoxine-pyrimethamine for the prevention of malaria-associated low birth weight. *Am J Trop Med Hyg* 2001; 64:178.
144. Garner P, Gülmezoglu AM. Drugs for preventing malaria-related illness in pregnant women and death in the newborn. *Cochrane Database Syst Rev* 2003; :CD000169.
145. Wong LF, Wilkes J, Korgenski K, et al. Risk factors associated with preterm birth after a prior term delivery. *BJOG* 2016; 123:1772.
146. Rodrigues T, Barros H. Short interpregnancy interval and risk of spontaneous preterm delivery. *Eur J Obstet Gynecol Reprod Biol* 2008; 136:184.
147. Rodriguez MI, Chang R, Thiel de Bocanegra H. The impact of postpartum contraception on reducing preterm birth: findings from California. *Am J Obstet Gynecol* 2015; 213:703.e1.
148. Conde-Agudelo A, Rosas-Bermúdez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. *JAMA* 2006; 295:1809.
149. Mozurkewich EL, Luke B, Avni M, Wolf FM. Working conditions and adverse pregnancy outcome: a meta-analysis. *Obstet Gynecol* 2000; 95:623.
150. van Beukering MD, van Melick MJ, Mol BW, et al. Physically demanding work and preterm delivery: a systematic review and meta-analysis. *Int Arch Occup Environ Health* 2014; 87:809.
151. Saurel-Cubizolles MJ, Zeitlin J, Lelong N, et al. Employment, working conditions, and preterm birth: results from the Europop case-control survey. *J Epidemiol Community Health* 2004; 58:395.
152. Berkowitz GS, Papiernik E. Working conditions, maternity legislation, and preterm birth. *Semin Perinatol* 1995; 19:272.
153. Di Mascio D, Magro-Malosso ER, Saccone G, et al. Exercise during pregnancy in normal-weight women and risk of preterm birth: a systematic review and meta-analysis of randomized controlled trials. *Am J Obstet Gynecol* 2016; 215:561.
154. Aune D, Schlesinger S, Henriksen T, et al. Physical activity and the risk of preterm birth: a systematic review and meta-analysis of epidemiological studies. *BJOG* 2017; 124:1816.
155. Armson BA. Physical activity and preterm birth: risk factor or benefit? *BJOG* 2017; 124:1827.
156. Berghella V, Klebanoff M, McPherson C, et al. Sexual intercourse association with asymptomatic bacterial vaginosis and *Trichomonas vaginalis* treatment in relationship to preterm birth. *Am J Obstet Gynecol* 2002; 187:1277.
157. Read JS, Klebanoff MA. Sexual intercourse during pregnancy and preterm delivery: effects of vaginal microorganisms. The Vaginal Infections and Prematurity Study Group. *Am J Obstet Gynecol* 1993; 168:514.
158. Mills JL, Harlap S, Harley EE. Should coitus late in pregnancy be discouraged? *Lancet* 1981; 2:136.
159. Yost NP, Owen J, Berghella V, et al. Effect of coitus on recurrent preterm birth. *Obstet Gynecol* 2006; 107:793.
160. SIMPSON WJ. A preliminary report on cigarette smoking and the incidence of prematurity. *Am J Obstet Gynecol* 1957; 73:807.
161. Meyer MB, Tonascia JA. Maternal smoking, pregnancy complications, and perinatal mortality. *Am J Obstet Gynecol* 1977; 128:494.

162. Shiono PH, Klebanoff MA, Rhoads GG. Smoking and drinking during pregnancy. Their effects on preterm birth. *JAMA* 1986; 255:82.
163. Berkowitz GS, Papiernik E. Epidemiology of preterm birth. *Epidemiol Rev* 1993; 15:414.
164. Cnattingius S, Forman MR, Berendes HW, et al. Effect of age, parity, and smoking on pregnancy outcome: a population-based study. *Am J Obstet Gynecol* 1993; 168:16.
165. Harlow BL, Frigoletto FD, Cramer DW, et al. Determinants of preterm delivery in low-risk pregnancies. The RADIUS Study Group. *J Clin Epidemiol* 1996; 49:441.
166. Kyrklund-Blomberg NB, Cnattingius S. Preterm birth and maternal smoking: risks related to gestational age and onset of delivery. *Am J Obstet Gynecol* 1998; 179:1051.
167. http://www.cdc.gov/mmwr/volumes/65/wr/mm6532a4.htm?s_cid=mm6532a4_e.
168. Nicholson W, Croughan-Minihane M, Posner S, et al. Preterm delivery in patients admitted with preterm labor: a prediction study. *J Matern Fetal Med* 2001; 10:102.
169. Ney JA, Dooley SL, Keith LG, et al. The prevalence of substance abuse in patients with suspected preterm labor. *Am J Obstet Gynecol* 1990; 162:1562.
170. Spence MR, Williams R, DiGregorio GJ, et al. The relationship between recent cocaine use and pregnancy outcome. *Obstet Gynecol* 1991; 78:326.
171. Borges G, Lopez-Cervantes M, Medina-Mora ME, et al. Alcohol consumption, low birth weight, and preterm delivery in the National Addiction Survey (Mexico). *Int J Addict* 1993; 28:355.
172. Wilkins-Haug L, Gabow PA. Toluene abuse during pregnancy: obstetric complications and perinatal outcomes. *Obstet Gynecol* 1991; 77:504.
173. Boer K, Smit BJ, van Huis AM, Hogerzeil HV. Substance use in pregnancy: do we care? *Acta Paediatr Suppl* 1994; 404:65.
174. Almario CV, Seligman NS, Dysart KC, et al. Risk factors for preterm birth among opiate-addicted gravid women in a methadone treatment program. *Am J Obstet Gynecol* 2009; 201:326.e1.
175. Villar J, Gülmezoglu AM, de Onis M. Nutritional and antimicrobial interventions to prevent preterm birth: an overview of randomized controlled trials. *Obstet Gynecol Surv* 1998; 53:575.
176. Bloomfield FH, Oliver MH, Hawkins P, et al. A periconceptional nutritional origin for noninfectious preterm birth. *Science* 2003; 300:606.
177. Kumarasamy V, Mitchell MD, Bloomfield FH, et al. Effects of periconceptional undernutrition on the initiation of parturition in sheep. *Am J Physiol Regul Integr Comp Physiol* 2005; 288:R67.
178. Rayco-Solon P, Fulford AJ, Prentice AM. Maternal preconceptional weight and gestational length. *Am J Obstet Gynecol* 2005; 192:1133.
179. Stein Z, Susser M. The Dutch famine, 1944-1945, and the reproductive process. I. Effects on six indices at birth. *Pediatr Res* 1975; 9:70.
180. Kramer MS. Isocaloric balanced protein supplementation in pregnancy. *Cochrane Database Syst Rev* 2000; :CD000118.
181. Ota E, Tobe-Gai R, Mori R, Farrar D. Antenatal dietary advice and supplementation to increase energy and protein intake. *Cochrane Database Syst Rev* 2012; :CD000032.

182. Vahratian A, Siega-Riz AM, Savitz DA, Thorp JM Jr. Multivitamin use and the risk of preterm birth. *Am J Epidemiol* 2004; 160:886.
183. Fawzi WW, Msamanga GI, Urassa W, et al. Vitamins and perinatal outcomes among HIV-negative women in Tanzania. *N Engl J Med* 2007; 356:1423.
184. Spinnato JA 2nd, Freire S, Pinto e Silva JL, et al. Antioxidant supplementation and premature rupture of the membranes: a planned secondary analysis. *Am J Obstet Gynecol* 2008; 199:433.e1.
185. Rumbold A, Ota E, Nagata C, et al. Vitamin C supplementation in pregnancy. *Cochrane Database Syst Rev* 2015; :CD004072.
186. Rumbold A, Ota E, Hori H, et al. Vitamin E supplementation in pregnancy. *Cochrane Database Syst Rev* 2015; :CD004069.
187. Saccone G, Berghella V. Folic acid supplementation in pregnancy to prevent preterm birth: a systematic review and meta-analysis of randomized controlled trials. *Eur J Obstet Gynecol Reprod Biol* 2016; 199:76.
188. Pérez-López FR, Pasupuleti V, Mezones-Holguin E, et al. Effect of vitamin D supplementation during pregnancy on maternal and neonatal outcomes: a systematic review and meta-analysis of randomized controlled trials. *Fertil Steril* 2015; 103:1278.
189. Catov JM, Bodnar LM, Ness RB, et al. Association of periconceptional multivitamin use and risk of preterm or small-for-gestational-age births. *Am J Epidemiol* 2007; 166:296.
190. Han Z, Mulla S, Beyene J, et al. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. *Int J Epidemiol* 2011; 40:65.
191. McDonald SD, Han Z, Mulla S, et al. Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses. *BMJ* 2010; 341:c3428.
192. Cnattingius S, Villamor E, Johansson S, et al. Maternal obesity and risk of preterm delivery. *JAMA* 2013; 309:2362.
193. Girsen AI, Mayo JA, Carmichael SL, et al. Women's prepregnancy underweight as a risk factor for preterm birth: a retrospective study. *BJOG* 2016; 123:2001.
194. Honest H, Bachmann LM, Ngai C, et al. The accuracy of maternal anthropometry measurements as predictor for spontaneous preterm birth--a systematic review. *Eur J Obstet Gynecol Reprod Biol* 2005; 119:11.
195. Carmichael SL, Abrams B. A critical review of the relationship between gestational weight gain and preterm delivery. *Obstet Gynecol* 1997; 89:865.
196. Dietz PM, Callaghan WM, Cogswell ME, et al. Combined effects of prepregnancy body mass index and weight gain during pregnancy on the risk of preterm delivery. *Epidemiology* 2006; 17:170.
197. Schieve LA, Cogswell ME, Scanlon KS, et al. Prepregnancy body mass index and pregnancy weight gain: associations with preterm delivery. The NMIHS Collaborative Study Group. *Obstet Gynecol* 2000; 96:194.
198. Thangaratinam S, Rogozinska E, Jolly K, et al. Effects of interventions in pregnancy on maternal weight and obstetric outcomes: meta-analysis of randomised evidence. *BMJ* 2012; 344:e2088.

199. Myklestad K, Vatten LJ, Magnussen EB, et al. Do parental heights influence pregnancy length?: A population-based prospective study, HUNT 2. *BMC Pregnancy Childbirth* 2013; 13:33.
200. Derraik JG, Lundgren M, Cutfield WS, Ahlsson F. Maternal Height and Preterm Birth: A Study on 192,432 Swedish Women. *PLoS One* 2016; 11:e0154304.
201. Han Z, Lutsiv O, Mulla S, McDonald SD. Maternal height and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. *J Obstet Gynaecol Can* 2012; 34:721.
202. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6409a3.htm?s_cid=mm6409a3_e.
203. Lockwood CJ. Stress-associated preterm delivery: the role of corticotropin-releasing hormone. *Am J Obstet Gynecol* 1999; 180:S264.
204. Petraglia F, Hatch MC, Lapinski R, et al. Lack of effect of psychosocial stress on maternal corticotropin-releasing factor and catecholamine levels at 28 weeks' gestation. *J Soc Gynecol Investig* 2001; 8:83.
205. Lu MC, Chen B. Racial and ethnic disparities in preterm birth: the role of stressful life events. *Am J Obstet Gynecol* 2004; 191:691.
206. Kramer MS, Lydon J, Séguin L, et al. Stress pathways to spontaneous preterm birth: the role of stressors, psychological distress, and stress hormones. *Am J Epidemiol* 2009; 169:1319.
207. Lima SAM, El Dib RP, Rodrigues MRK, et al. Is the risk of low birth weight or preterm labor greater when maternal stress is experienced during pregnancy? A systematic review and meta-analysis of cohort studies. *PLoS One* 2018; 13:e0200594.
208. Chen MJ, Grobman WA, Gollan JK, Borders AE. The use of psychosocial stress scales in preterm birth research. *Am J Obstet Gynecol* 2011; 205:402.
209. Hodnett ED, Fredericks S. Support during pregnancy for women at increased risk of low birthweight babies. *Cochrane Database Syst Rev* 2003; :CD000198.
210. Khianman B, Pattanittum P, Thinkhamrop J, Lumbiganon P. Relaxation therapy for preventing and treating preterm labour. *Cochrane Database Syst Rev* 2012; :CD007426.
211. Li X, Huang S, Jiao A, et al. Association between ambient fine particulate matter and preterm birth or term low birth weight: An updated systematic review and meta-analysis. *Environ Pollut* 2017; 227:596.
212. Sun X, Luo X, Zhao C, et al. The association between fine particulate matter exposure during pregnancy and preterm birth: a meta-analysis. *BMC Pregnancy Childbirth* 2015; 15:300.
213. Stieb DM, Chen L, Eshoul M, Judek S. Ambient air pollution, birth weight and preterm birth: a systematic review and meta-analysis. *Environ Res* 2012; 117:100.
214. Casey JA, Karasek D, Ogburn EL, et al. Coal and oil power plant retirements in California associated with reduced preterm birth among populations nearby. *Am J Epidemiol* 2018.
215. Whitworth M, Quenby S, Cockerill RO, Dowswell T. Specialised antenatal clinics for women with a pregnancy at high risk of preterm birth (excluding multiple pregnancy) to improve maternal and infant outcomes. *Cochrane Database Syst Rev* 2011; :CD006760.
216. Zeitlin J, Saurel-Cubizolles MJ, De Mouzon J, et al. Fetal sex and preterm birth: are males at greater risk? *Hum Reprod* 2002; 17:2762.
217. Ingemarsson I. Gender aspects of preterm birth. *BJOG* 2003; 110 Suppl 20:34.

218. Zeitlin J, Ancel PY, Larroque B, et al. Fetal sex and indicated very preterm birth: results of the EPIPAGE study. *Am J Obstet Gynecol* 2004; 190:1322.
219. McGregor JA, Leff M, Orleans M, Baron A. Fetal gender differences in preterm birth: findings in a North American cohort. *Am J Perinatol* 1992; 9:43.
220. Dolan SM, Gross SJ, Merkatz IR, et al. The contribution of birth defects to preterm birth and low birth weight. *Obstet Gynecol* 2007; 110:318.
221. Purisch SE, DeFranco EA, Muglia LJ, et al. Preterm birth in pregnancies complicated by major congenital malformations: a population-based study. *Am J Obstet Gynecol* 2008; 199:287.e1.
222. Lackman F, Capewell V, Richardson B, et al. The risks of spontaneous preterm delivery and perinatal mortality in relation to size at birth according to fetal versus neonatal growth standards. *Am J Obstet Gynecol* 2001; 184:946.
223. Morken NH, Källen K, Jacobsson B. Fetal growth and onset of delivery: a nationwide population-based study of preterm infants. *Am J Obstet Gynecol* 2006; 195:154.
224. Ott WJ. Intrauterine growth retardation and preterm delivery. *Am J Obstet Gynecol* 1993; 168:1710.
225. Zeitlin J, Ancel PY, Saurel-Cubizolles MJ, Papiernik E. The relationship between intrauterine growth restriction and preterm delivery: an empirical approach using data from a European case-control study. *BJOG* 2000; 107:750.
226. Gardosi JO. Prematurity and fetal growth restriction. *Early Hum Dev* 2005; 81:43.
227. Wadhwa PD, Garite TJ, Porto M, et al. Placental corticotropin-releasing hormone (CRH), spontaneous preterm birth, and fetal growth restriction: a prospective investigation. *Am J Obstet Gynecol* 2004; 191:1063.
228. Basso O, Olsen J, Christensen K. Low birthweight and prematurity in relation to paternal factors: a study of recurrence. *Int J Epidemiol* 1999; 28:695.
229. Boyd HA, Poulsen G, Wohlfahrt J, et al. Maternal contributions to preterm delivery. *Am J Epidemiol* 2009; 170:1358.
230. Meertens LJE, van Montfort P, Scheepers HCJ, et al. Prediction models for the risk of spontaneous preterm birth based on maternal characteristics: a systematic review and independent external validation. *Acta Obstet Gynecol Scand* 2018.
231. Honest H, Bachmann LM, Sundaram R, et al. The accuracy of risk scores in predicting preterm birth--a systematic review. *J Obstet Gynaecol* 2004; 24:343.
232. Hezelgrave NL, Abbott DS, Radford SK, et al. Quantitative Fetal Fibronectin at 18 Weeks of Gestation to Predict Preterm Birth in Asymptomatic High-Risk Women. *Obstet Gynecol* 2016; 127:255.
233. Kuhrt K, Smout E, Hezelgrave N, et al. Development and validation of a tool incorporating cervical length and quantitative fetal fibronectin to predict spontaneous preterm birth in asymptomatic high-risk women. *Ultrasound Obstet Gynecol* 2016; 47:104.
234. www.QUIPP.org.
235. Esplin MS, Elovitz MA, Iams JD, et al. Predictive Accuracy of Serial Transvaginal Cervical Lengths and Quantitative Vaginal Fetal Fibronectin Levels for Spontaneous Preterm Birth Among Nulliparous Women. *JAMA* 2017; 317:1047.

236. Saade GR, Boggess KA, Sullivan SA, et al. Development and validation of a spontaneous preterm delivery predictor in asymptomatic women. *Am J Obstet Gynecol* 2016; 214:633.e1.
237. Conde-Agudelo A, Papageorghiou AT, Kennedy SH, Villar J. Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis. *BJOG* 2011; 118:1042.
238. van Vliet EO, Askie LA, Mol BW, Oudijk MA. Antiplatelet Agents and the Prevention of Spontaneous Preterm Birth: A Systematic Review and Meta-analysis. *Obstet Gynecol* 2017; 129:327.
239. Andrikopoulou M, Purisch SE, Handal-Orefice R, Gyamfi-Bannerman C. Low-dose aspirin is associated with reduced spontaneous preterm birth in nulliparous women. *Am J Obstet Gynecol* 2018; 219:399.e1.
240. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. *Obstet Gynecol* 2018; 132:e44.
241. Heida KY, Velthuis BK, Oudijk MA, et al. Cardiovascular disease risk in women with a history of spontaneous preterm delivery: A systematic review and meta-analysis. *Eur J Prev Cardiol* 2016; 23:253.

Topic 6761 Version 89.0

GRAPHICS

Definitions for preterm birth

Gestational age criteria	
World Health Organization	
Moderate to late preterm	32 to <37 weeks
Very preterm	28 to <32 weeks
Extremely preterm	<28 weeks
Centers for Disease Control and Prevention	
Preterm	<37 weeks
Late preterm	34 to 36 weeks
Early preterm	<34 weeks
Birth weight criteria	
Low birth weight (LBW)	<2500 grams
Very low birth weight (VLBW)	<1500 grams
Extremely low birth weight (ELBW)	<1000 grams

The lower gestational age limit of preterm birth is 20+0 weeks of gestation. A birth <20 weeks of gestation is called a pregnancy loss, miscarriage, or spontaneous abortion in the United States. Preterm births are described by gestational age, birth weight, and initiating factor (eg, spontaneous preterm birth versus medically indicated preterm birth).

Graphic 113391 Version 1.0

Risk factors for preterm birth

No partner
Low socioeconomic level
Anxiety, stress
Depression, use of selective serotonin inhibitors
Life events (divorce, separation, death)
Abdominal surgery during pregnancy
Occupational issues (upright posture, use of industrial machines, physical exertion, mental or environmental stress related to work or working conditions)
Multiple gestation
Polyhydramnios
Uterine anomaly, including diethylstilbestrol-induced changes in uterus and leiomyomas
Preterm premature rupture of membranes
History of second-trimester abortion
History of cervical surgery
Premature cervical dilatation or effacement (short cervical length)
Sexually transmitted infections
Systemic infection, pyelonephritis, appendicitis, pneumonia
Bacteriuria
Periodontal disease
Placenta previa
Placental abruption
Vaginal bleeding, especially in more than one trimester
Previous preterm delivery
Substance abuse
Smoking
Maternal age (<18 or >40)
African-American race
Poor nutrition and low body mass index
Inadequate prenatal care
Anemia (hemoglobin <10 g/dL)
Excessive uterine contractility
Low level of educational achievement
Maternal first-degree family history of spontaneous preterm birth, especially if the pregnant woman herself was born preterm
Fetal anomaly
Fetal growth restriction
Environmental factors (eg, heat, air pollution)
Fetal demise
Positive fetal fibronectin test result in vaginal secretions

Risk of recurrent spontaneous preterm birth in a second pregnancy

	Risk of PTB in next pregnancy (%)	Risk of PTB before 28 weeks of gestation (%)
No prior PTB	9	0.23
Prior PTB	22	
Prior PTB at 23 to 27 weeks		5
Prior PTB at 28 to 34 weeks		3
Prior PTB at 35 to 36 weeks		1

PTB: preterm birth.

Data from: Mercer BM, Goldenberg RL, Moawad AH, et al. The preterm prediction study: Effect of gestational age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1999; 181:1216.

Graphic 58321 Version 6.0

Risk of preterm birth in a third pregnancy

Obstetric history	Risk of PTB in third pregnancy (%)
Two prior preterm births	42
Both at 32 to 36 weeks	33
Both at less than 32 weeks	57
Term birth followed by PTB	21
PTB followed by term birth	13
Two prior term births	5

These data were derived from women with spontaneous or indicated preterm birth.

PTB: preterm birth.

Data from: McManemy J, Cooke E, Amon E, Leet T. Recurrence risk for preterm delivery. Am J Obstet Gynecol 2007; 196:576.

Graphic 73926 Version 7.0

Management of women with previous preterm delivery or second trimester loss

Patient population	Interventions to be considered	Options in next pregnancy if history-indicated cerclage was not successful (ie, preterm birth <33 weeks)
Women with: <ul style="list-style-type: none"> ▪ ≥2 consecutive prior second-trimester losses*, or ▪ ≥3 early (<34 weeks) preterm births 	Transvaginal cerclage at 12 to 14 weeks and Hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks	Transabdominal cerclage Hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks
Women with: <ul style="list-style-type: none"> ▪ One prior second-trimester loss*, or ▪ One or two preterm births 	Hydroxyprogesterone caproate 250 mg IM weekly from 16 to 36 weeks Serial measurement of cervical length beginning at 14 to 16 weeks and ending at 24 weeks If cervical length ≤25 mm before 24 weeks, place transvaginal cerclage	

* Usually a spontaneous pregnancy loss between 16 and 27 6/7ths weeks of gestation.

Data from: Iams JD, Berghella V. Care for women with prior preterm birth. *Am J Obstet Gynecol* 2010; 203:89.

Graphic 71782 Version 5.0

Relative risk of preterm delivery as a function of cervical length

Cervical length (mm)	Centile	Relative risk of PTD	Confidence interval
≤35	50	2.35	1.42 to 3.89
≤30	25	3.79	2.32 to 6.19
≤26	10	6.19	3.84 to 9.97
≤22	5	9.49	5.95 to 15.15
≤13	1	13.99	7.89 to 24.78

Relative risk is in comparison to women whose cervical lengths were above the 75th percentile. Data from an asymptomatic general obstetrical population evaluated between 22 and 30 weeks of gestation with exclusion of women with multiple gestations, fetal anomalies, cerclage, or placental previa.

PTD: preterm delivery.

Data from: Iams JD, Goldenberg RL, Meis PJ, et al. The length of the cervix and the risk of spontaneous premature delivery. National Institute of Child Health and Human Development Maternal Fetal Medicine Unit Network. N Engl J Med 1996; 334:567.

Graphic 56052 Version 6.0

Risk of preterm birth with selected infections

Infection	Odds ratio (95% CI)
Bacterial vaginosis before 16 weeks	7.55 (1.8-31.7)
<i>N. gonorrhoeae</i>	5.31 (1.57-17.9)
Asymptomatic bacteriuria	2.08 (1.45-3.03)
<i>Chlamydia trachomatis</i>	
at 24 weeks	2.2 (1.03-4.78)
at 28 weeks	0.95 (0.36-2.47)
<i>Trichomonas vaginalis</i>	1.3 (1.1-1.4)
<i>U. urealyticum</i>	1.0 (0.8-1.2)

Data from: Klein LL, Gibbs RS. Use of microbial cultures and antibiotics in the prevention of infection-associated preterm birth. *Am J Obstet Gynecol* 2004; 190:1493.

Graphic 63047 Version 5.0

Working conditions and the risk of adverse pregnancy outcome


Work parameter	Odds ratio for preterm birth	Odds ratio for SGA infant	Confidence interval
Physically demanding work (lifting, load carrying, manual labor, or significant physical exertion)	1.22		1.15, 1.29
		1.37	1.30, 1.44
Prolonged standing (>3 hours/day)	1.26		1.13, 1.40
Shift or night work	1.24		1.06, 1.46
Long working hours	1.03		0.92, 1.16
High cumulative work fatigue score	1.63		1.33, 1.98

SGA: small for gestational age.

Data from: Mozurkewich EL, Luke B, Avni M, Wolf FM. Working conditions and adverse pregnancy outcome: a meta-analysis. *Obstet Gynecol* 2000; 95:623.

Graphic 51860 Version 2.0

Pathogenesis of spontaneous preterm birth



HPA: hypothalamus-pituitary-adrenal; ACTH: Adrenocorticotropic hormone 16-OH; DHEA: 16-hydroxydehydroepiandrosterone; E1 - E3: estrogen, estradiol, estrone; CRH: Corticotropin releasing hormone; Cox-2: Cyclooxygenase 2; PG: Prostaglandin; MLCK: Myosin light chain kinase; PROM: Premature rupture of membranes; PGDH: Hydroxyprostaglandin dehydrogenase

Graphic 59393 Version 3.0

Contributor Disclosures

Julian N Robinson, MD Nothing to disclose **Errol R Norwitz, MD, PhD, MBA** Grant/Research/Clinical Trial Support: Illumina [Preeclampsia (primary investigator on a prospective cohort study to collect samples from patients with preeclampsia to facilitate development of a biomarker test to predict/diagnose this disorder)]. Consultant/Advisory Boards: Hologic [Preterm birth (Fetal fibronectin test to predict preterm birth)]; Natara [Fetal aneuploidy testing (NIPT as a screening test for fetal aneuploidy)]; Seracare [Fetal aneuploidy testing (Developing controls for NIPT screening test for fetal aneuploidy)]; Bayer [Prediction test for preeclampsia (Use of urinary angiogenic factors to predict preeclampsia)]. **Charles J Lockwood, MD, MHCM** Nothing to disclose **Vanessa A Barss, MD, FACOG** Nothing to disclose

Contributor disclosures are reviewed for conflicts of interest by the editorial group. When found, these are addressed by vetting through a multi-level review process, and through requirements for references to be provided to support the content. Appropriately referenced content is required of all authors and must conform to UpToDate standards of evidence.

[Conflict of interest policy](#)